Patent Grant
11679132
The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on Jul. 11, 2022, is named 62190_701_303 SL.xml and is 87,728 bytes in size.
Immune cells can be potent and specific “living drugs”. Immune cells have the potential to target tumor cells while sparing normal tissues; several clinical observations indicate that they can have major anti-cancer activity. Thus, in patients receiving allogeneic hematopoietic stem cell transplantation (HSCT), T-cell-mediated graft-versus-host disease (GvHD) (Weiden, P L et al., N. Engl. J. Med. 1979; 300(19):1068-1073; Appelbaum, FR Nature, 2001; 411(6835):385-389; Porter, D L et al., N. Engl. J. Med. 1994; 330(2):100-106; Kolb, H J et al. Blood. 1995; 86(5):2041-2050; Slavin, S. et al., Blood. 1996; 87(6):2195-2204), and donor natural killer (NK) cell alloreactivity (Ruggeri L, et al. Science. 2002; 295(5562):2097-2100; Giebel S, et al. Blood. 2003; 102(3):814-819; Cooley S, et al. Blood. 2010; 116(14):2411-2419) are inversely related to leukemia recurrence. Besides the HSCT context, administration of antibodies that release T cells from inhibitory signals (Sharma P, et al., Nat Rev Cancer. 2011; 11(11):805-812; Pardoll D M., Nat Rev Cancer. 2012; 12(4):252-264), or bridge them to tumor cells (Topp M S, et al. J. Clin. Oncol. 2011; 29(18):2493-2498) produced major clinical responses in patients with either solid tumors or leukemia. Finally, infusion of genetically-modified autologous T lymphocytes induced complete and durable remission in patients with refractory leukemia and lymphoma (Maude S L, et al. N Engl J Med. 2014; 371(16):1507-1517).
Nevertheless, there is a significant need for improving immune cell therapy by broadening its applicability and enhancing its efficacy.
The present invention relates to engineered immune cells having enhanced therapeutic efficacy for, e.g., cancer therapy. In certain embodiments, the present invention provides an engineered immune cell that comprises a nucleic acid comprising a nucleotide sequence encoding an immune activating receptor, and a nucleic acid comprising a nucleotide sequence encoding a target-binding molecule linked to a localizing domain.
In other embodiments, the present invention provides the use of an engineered immune cell that comprises a gene encoding an immune activating receptor, and a gene encoding a target-binding molecule linked to a localizing domain for treating cancer, comprising administering a therapeutic amount of the engineered immune cell to a subject in need thereof.
In various embodiments, the present invention also provides a method for producing an engineered immune cell, the method comprising introducing into an immune cell a nucleic acid comprising a nucleotide sequence encoding an immune activating receptor, and a nucleic acid comprising a nucleotide sequence encoding a target-binding molecule linked to a localizing domain, thereby producing an engineered immune cell.
In some embodiments, the engineered immune cells possess enhanced therapeutic efficacy as a result of one or more of reduced graft-versus-host disease (GvHD) in a host, reduced or elimination of rejection by a host, extended survival in a host, reduced inhibition by the tumor in a host, reduced self-killing in a host, reduced inflammatory cascade in a host, or sustained natural/artificial receptor-mediated (e.g., CAR-mediated) signal transduction in a host.
The foregoing will be apparent from the following more particular description of example embodiments of the invention, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating embodiments of the present invention.
A description of example embodiments of the invention follows.
In recent years, gains in knowledge about the molecular pathways that regulate immune cells have been paralleled by a remarkable evolution in the capacity to manipulate them ex vivo, including their expansion and genetic engineering. It is now possible to reliably prepare highly sophisticated clinical-grade immune cell products in a timely fashion. A prime example of how the anti-cancer activity of immune cells can be directed and magnified by ex vivo cell engineering is the development of chimeric antigen receptor (CAR) T cells (Eshhar, Z. et al., PNAS. 1993; 90(2):720-724).
CARs are artificial multi-molecular proteins, which have been previously described (Geiger T L, et al., J Immunol. 1999; 162(10):5931-5939; Brentjens R J, et al., NatMed. 2003; 9(3):279-286; Cooper L J, et al., Blood. 2003; 101(4):1637-1644). CARs comprise an extracellular domain that binds to a specific target, a transmembrane domain, and a cytoplasmic domain. The extracellular domain and transmembrane domain can be derived from any desired source for such domains, as described in, e.g., U.S. Pat. No. 8,399,645, incorporated by reference herein in its entirety. Briefly, a CAR may be designed to contain a single-chain variable region (scFv) of an antibody that binds specifically to a target. The scFv may be linked to a T-cell receptor (TCR)-associated signaling molecule, such as CD3ζ, via transmembrane and hinge domains. Ligation of scFv to the cognate antigen triggers signal transduction. Thus, CARs can instantaneously redirect cytotoxic T lymphocytes towards cancer cells and provoke tumor cell lysis (Eshhar, Z. et al., PNAS. 1993; 90(2):720-724; Geiger T L, et al., J Immunol. 1999; 162(10):5931-5939; Brentjens R J, et al., NatMed. 2003; 9(3):279-286; Cooper L J, et al., Blood. 2003; 101(4):1637-1644; Imai C, et al., Leukemia. 2004; 18:676-684). Because CD3ζ signaling alone is not sufficient to durably activate T cells (Schwartz R H. Annu Rev Immunol. 2003; 21:305-334; Zang X and Allison J P. Clin Cancer Res. 2007; 13(18 Pt 1):5271-5279), co-stimulatory molecules such as CD28 and 4-1BB (or CD137) have been incorporated into CAR constructs to boost signal transduction. This dual signaling design (“second generation CAR”) is useful to elicit effective anti-tumor activity from T cells (Imai C, et al., Leukemia. 2004; 18:676-684; Campana D, et al., Cancer J. 2014; 20(2):134-140).
A specific CAR, anti-CD19 CAR, containing both 4-1BB and CD3ζ has been described in U.S. Pat. No. 8,399,645. Infusion of autologous T cells expressing an anti-CD19-4-1BB-CD3ζ CAR resulted in dramatic clinical responses in patients with chronic lymphocytic leukemia (CLL) (Porter D L, et al., Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia; 2011: N Engl J Med. 2011; 365(8):725-733; Kalos M, et al., SciTranslMed. 2011; 3(95):95ra73), and acute lymphoblastic leukemia (ALL) (Grupp S A, et al., N Engl J Med. 2013; 368(16):1509-1518; Maude S L, et al., N Engl J Med. 2014; 371(16):1507-1517). These studies, and studies with CARs bearing different signaling modules (Till B G, et al., Blood. 2012; 119(17):3940-3950; Kochenderfer J N, et al., Blood. 2012; 119(12):2709-2720; Brentjens R J, et al., Blood. 2011; 118(18):4817-4828; Brentjens R J, et al., Sci Transl Med. 2013; 5(177):177ra138), provide a convincing demonstration of the clinical potential of this technology, and of immunotherapy in general.
The methods described herein enable rapid removal or inactivation of specific proteins in immune cells redirected by a natural or artificial receptor, e.g., CARs, thus broadening the application potential and significantly improving the function of the engineered cells. The method relies, in part, on a single construct or multiple constructs containing an immune activating receptor, e.g., a CAR (which comprises an extracellular domain (e.g., an scFv) that binds to a specific target, a transmembrane domain, and a cytoplasmic domain) together with a target-binding molecule that binds a target (e.g., protein) to be removed or neutralized; the target-binding molecule is linked to a domain (i.e., localizing domain) that directs it to specific cellular compartments, such as the Golgi or endoplasmic reticulum, the proteasome, or the cell membrane, depending on the application. For simplicity, a target-binding molecule linked to a localizing domain (LD) is sometimes referred to herein as “LD-linked target-binding molecule.”
As will be apparent from the teachings herein, a variety of immune activating receptors may be suitable for the methods of the present invention. That is, any receptor that comprises a molecule that, upon binding (ligation) to a ligand (e.g., peptide or antigen) expressed on a cancer cell, is capable of activating an immune response may be used according to the present methods. For example, as described above, the immune activating receptor can be a chimeric antigen receptor (CAR); methods for designing and manipulating a CAR is known in the art (see, Geiger T L, et al., J Immunol. 1999; 162(10):5931-5939; Brentjens R J, et al., NatMed. 2003; 9(3):279-286; Cooper L J, et al., Blood. 2003; 101(4):1637-1644). Additionally, receptors with antibody-binding capacity can be used (e.g., CD16-4-1BB-CD3zeta receptor—Kudo K, et al. Cancer Res. 2014; 74(1):93-103), which are similar to CARs, but with the scFv replaced with an antibody-binding molecule (e.g., CD16, CD64, CD32). Further, T-cell receptors comprising T-cell receptor alpha and beta chains that bind to a peptide expressed on a tumor cell in the context of the tumor cell HLA can also be used according to the present methods. In addition, other receptors bearing molecules that activate an immune response by binding a ligand expressed on a cancer cell can also be used—e.g., NKG2D-DAP10-CD3zeta receptor, which binds to NKG2D ligand expressed on tumor cells (see, e.g., Chang Y H, et al., Cancer Res. 2013; 73(6):1777-1786). All such suitable receptors collectively, as used herein, are referred to as an “immune activating receptor” or a “receptor that activates an immune response upon binding a cancer cell ligand.” Therefore, an immune activating receptor having a molecule activated by a cancer cell ligand can be expressed together with a LD-linked target-binding molecule according to the present methods.
The present methods significantly expand the potential applications of immunotherapies based on the infusion of immune cells redirected by artificial receptors. The method described is practical and can be easily incorporated in a clinical-grade cell processing. For example, a single bicistronic construct containing, e.g., a CAR and a LD-linked target-binding molecule, e.g., scFv-myc KDEL (or PEST or transmembrane) can be prepared by inserting an internal ribosomal entry site (IRES) or a 2A peptide-coding region site between the 2 cDNAs encoding the CAR and the LD-linked target-binding molecule. The design of tricistronic delivery systems to delete more than one target should also be feasible. Alternatively, separate transductions of the 2 genes (simultaneously or sequentially) could be performed. In the context of cancer cell therapy, the CAR could be replaced by an antibody-binding signaling receptor (Kudo K, et al., Cancer Res. 2014; 74(1):93-103), a T-cell receptor directed against a specific HLA-peptide combination, or any receptor activated by contact with cancer cells (Chang Y H, et al., Cancer Res. 2013; 73(6):1777-1786). The results of the studies described herein with simultaneous anti-CD19-4-1BB-CD3ζ CAR and anti-CD3ε scFv-KDEL demonstrate that the signaling capacity of the CAR was not impaired.
Both the anti-CD3ε scFv-KDEL (and -PEST) tested herein stably downregulate CD3 as well as TCR expression. Residual CD3+ T cells could be removed using CD3 beads, an approach that is also available in a clinical-grade format. The capacity to generate CD3/TCR-negative cells that respond to CAR signaling represents an important advance. Clinical studies with CAR T cells have generally been performed using autologous T cells. Thus, the quality of the cell product varies from patient to patient and responses are heterogeneous. Infusion of allogeneic T cells is currently impossible as it has an unacceptably high risk of potentially fatal GvHD, due to the stimulation of the endogenous TCR by the recipient's tissue antigens. Downregulation of CD3/TCR opens the possibility of infusing allogeneic T cells because lack of endogenous TCR eliminates GvHD capacity. Allogeneic products could be prepared with the optimal cellular composition (e.g., enriched in highly cytotoxic T cells, depleted of regulatory T cells, etc.) and selected so that the cells infused have high CAR expression and functional potency. Moreover, fully standardized products could be cryopreserved and be available for use regardless of the patient immune cell status and his/her fitness to undergo apheresis or extensive blood draws. Removal of TCR expression has been addressed using gene editing tools, such as nucleases (Torikai H, et al. Blood, 2012; 119(24):5697-5705). Although this is an effective approach, it is difficult to implement in a clinical setting as it requires several rounds of cell selection and expansion, with prolonged culture. The methods described herein have considerable practical advantages.
Additionally, a LD-linked target-binding molecule (e.g., scFv-myc KDEL, scFv-EEKKMP or scFv-PEST, wherein scFv targets a specific protein/molecule) can be used according to the present invention to delete HLA Class I molecules, reducing the possibility of rejection of allogeneic cells. While infusion of allogeneic T cells is a future goal of CAR T cell therapy, infusion of allogeneic natural killer (NK) cells is already in use to treat patients with cancer. A key factor that determines the success of NK cell-based therapy is that NK cells must persist in sufficient numbers to achieve an effector: target ratio likely to produce tumor cytoreduction (Miller J S. Hematology Am Soc Hematol Educ Program. 2013; 2013:247-253). However, when allogeneic cells are infused, their persistence is limited. Immunosuppressive chemotherapy given to the patient allows transient engraftment of the infused NK cells but these are rejected within 2-4 weeks of infusion (Miller J S, et al. Blood. 2005; 105:3051-3057; Rubnitz J E, et al., J Clin Oncol. 2010; 28(6):955-959). Contrary to organ transplantation, continuing immunosuppression is not an option because immunosuppressive drugs also suppress NK cell function. Because rejection is primarily mediated by recognition of HLA Class I molecules by the recipient's CD8+T lymphocytes, removing HLA Class I molecules from the infused NK cells (or T cells) will diminish or abrogate the rejection rate, extend the survival of allogeneic cells, and hence their anti-tumor capacity.
Furthermore, a LD-linked target-binding molecule can be used according to the present invention to target inhibitory receptors. Specifically, administration of antibodies that release T cells from inhibitory signals such as anti-PD1 or anti-CTLA-4 have produced dramatic clinical responses (Sharma P, et al., Nat Rev Cancer. 2011; 11(11):805-812; Pardoll D M. Nat Rev Cancer. 2012; 12(4):252-264). CAR-T cells, particularly those directed against solid tumors, might be inhibited by similar mechanisms. Thus, expression of a target-binding molecule (e.g., scFv or ligands) against PD1, CTLA-4, Tim3 or other inhibitory receptors would prevent the expression of these molecules (if linked to, e.g., KDEL (SEQ ID NO: 4), EEKKMP (SEQ ID NO: 64) or PEST motif SHGFPPEVEEQDDGTLPMSCAQESGMDRHPAACASARINV (SEQ ID NO: 7)) or prevent binding of the receptors to their ligands (if linked to a transmembrane domain) and sustain CAR-mediated signal transduction. In NK cells, examples of inhibitory receptors include killer immunoglobulin-like receptors (KIRs) and NKG2A (Vivier E, et al., Science, 2011; 331(6013):44-49).
The methods of the present invention also enable targeting of a greater number of targets amenable for CAR-directed T cell therapy. One of the main limitations of CAR-directed therapy is the paucity of specific antigens expressed by tumor cells. In the case of hematologic malignancies, such as leukemias and lymphomas, molecules which are not expressed in non-hematopoietic cells could be potential targets but cannot be used as CAR targets because they are also expressed on T cells and/or NK cells. Expressing such CARs on immune cells would likely lead to the demise of the immune cells themselves by a “fratricidal” mechanism, nullifying their anti-cancer capacity. If the target molecule can be removed from immune cells without adverse functional effects, then the CAR with the corresponding specificity can be expressed. This opens many new opportunities to target hematologic malignancies. Examples of the possible targets include CD38 expressed in multiple myeloma, CD7 expressed in T cell leukemia and lymphoma, Tim-3 expressed in acute leukemia, CD30 expressed in Hodgkin disease, CD45 and CD52 expressed in all hematologic malignancies. These molecules are also expressed in a substantial proportion of T cells and NK cells.
Moreover, it has been shown that secretion of cytokines by activated immune cells triggers cytokine release syndrome and macrophage activation syndrome, presenting serious adverse effects of immune cell therapy (Lee D W, et al., Blood. 2014; 124(2):188-195). Thus, the LD-linked target-binding molecule can be used according to the present invention to block cytokines such as IL-6, IL-2, IL-4, IL-7, IL-10, IL-12, IL-15, IL-18, IL-21, IL-27, IL-35, interferon (IFN)-γ, IFN-β, IFN-α, tumor necrosis factor (TNF)-α, and transforming growth factor (TGF)-β, which may contribute to such inflammatory cascade.
Accordingly, in one embodiment, the present invention relates to an engineered immune cell that comprises a nucleic acid comprising a nucleotide sequence encoding an immune activating receptor, and a nucleic acid comprising a nucleotide sequence encoding a target-binding molecule linked to a localizing domain.
As used herein, an “engineered” immune cell includes an immune cell that has been genetically modified as compared to a naturally-occurring immune cell. For example, an engineered T cell produced according to the present methods carries a nucleic acid comprising a nucleotide sequence that does not naturally occur in a T cell from which it was derived. In some embodiments, the engineered immune cell of the present invention includes a chimeric antigen receptor (CAR) and a target-binding molecule linked to a localizing domain (LD-linked target-binding molecule). In a particular embodiment, the engineered immune cell of the present invention includes an anti-CD19-4-1BB-CD3ζ CAR and an anti-CD3 scFv linked to a localizing domain.
In certain embodiments, the engineered immune cell is an engineered T cell, an engineered natural killer (NK) cell, an engineered NK/T cell, an engineered monocyte, an engineered macrophage, or an engineered dendritic cell.
In certain embodiments, an “immune activating receptor” as used herein refers to a receptor that activates an immune response upon binding a cancer cell ligand. In some embodiments, the immune activating receptor comprises a molecule that, upon binding (ligation) to a ligand (e.g., peptide or antigen) expressed on a cancer cell, is capable of activating an immune response. In one embodiment, the immune activating receptor is a chimeric antigen receptor (CAR); methods for designing and manipulating a CAR are known in the art. In other embodiments, the immune activating receptor is an antibody-binding receptor, which is similar to a CAR, but with the scFv replaced with an antibody-binding molecule (e.g., CD16, CD64, CD32) (see e.g., CD16-4-1BB-CD3zeta receptor—Kudo K, et al. Cancer Res. 2014; 74(1):93-103). In various embodiments, T-cell receptors comprising T-cell receptor alpha and beta chains that bind to a peptide expressed on a tumor cell in the context of the tumor cell HLA can also be used according to the present methods. In certain embodiments, other receptors bearing molecules that activate an immune response by binding a ligand expressed on a cancer cell can also be used—e.g., NKG2D-DAP10-CD3zeta receptor, which binds to NKG2D ligand expressed on tumor cells (see, e.g., Chang Y H, et al., Cancer Res. 2013; 73(6):1777-1786). All such suitable receptors capable of activating an immune response upon binding (ligation) to a ligand (e.g., peptide or antigen) expressed on a cancer cell are collectively referred to as an “immune activating receptor.” As would be appreciated by those of skill in the art, an immune activating receptor need not contain an antibody or antigen-binding fragment (e.g., scFv); rather the portion of the immune activating receptor that binds to a target molecule can be derived from, e.g., a receptor in a receptor-ligand pair, or a ligand in a receptor-ligand pair.
In certain aspects, the immune activating receptor binds to molecules expressed on the surface of tumor cells, including but not limited to, CD20, CD22, CD33, CD2, CD3, CD4, CD5, CD7, CD8, CD45, CD52, CD38, CS-1, TIM3, CD123, mesothelin, folate receptor, HER2-neu, epidermal-growth factor receptor, and epidermal growth factor receptor. In some embodiments, the immune activating receptor is a CAR (e.g., anti-CD19-4-1BB-CD3ζ CAR). In certain embodiments, the immune activating receptor comprises an antibody or antigen-binding fragment thereof (e.g., scFv) that binds to molecules expressed on the surface of tumor cells, including but not limited to, CD20, CD22, CD33, CD2, CD3, CD4, CD5, CD7, CD8, CD45, CD52, CD38, CS-1, TIM3, CD123, mesothelin, folate receptor, HER2-neu, epidermal-growth factor receptor, and epidermal growth factor receptor. Antibodies to such molecules expressed on the surface of tumor cells are known and available in the art. By way of example, antibodies to CD3 and CD7 are commercially available and known in the art. Such antibodies, as well as fragments of antibodies (e.g., scFv) derived therefrom, can be used in the present invention, as exemplified herein. Further, methods of producing antibodies and antibody fragments against a target protein are well-known and routine in the art.
The transmembrane domain of an immune activating receptor according to the present invention (e.g., CAR) can be derived from a single-pass membrane protein, including, but not limited to, CD8α, CD8β, 4-1BB, CD28, CD34, CD4, FcεRIγ, CD16 (e.g., CD16A or CD16B), OX40, CD3ζ, CD3ε, CD3γ, CD3δ, TCRα, CD32 (e.g., CD32A or CD32B), CD64 (e.g., CD64A, CD64B, or CD64C), VEGFR2, FAS, and FGFR2B. In some examples, the membrane protein is not CD8α. The transmembrane domain may also be a non-naturally occurring hydrophobic protein segment.
The hinge domain of the immune activating receptor (e.g., CAR) can be derived from a protein such as CD8α, or IgG. The hinge domain can be a fragment of the transmembrane or hinge domain of CD8α, or a non-naturally occurring peptide, such as a polypeptide consisting of hydrophilic residues of varying length, or a (GGGGS)n(SEQ ID NO: 8) polypeptide, in which n is an integer of, e.g., 3-12, inclusive.
The signaling domain of the immune activating receptor (e.g., CAR) can be derived from CD3ζ, FcεRIγ, DAP10, DAP12 or other molecules known to deliver activating signals in immune cells. At least one co-stimulatory signaling domain of the receptor can be a co-stimulatory molecule such as 4-1BB (also known as CD137), CD28, CD28LL-*GG variant, OX40, ICOS, CD27, GITR, HVEM, TIM1, LFA1, or CD2. Such molecules are readily available and known in the art.
As would be appreciated by those of skill in the art, the components of an immune activating receptor can be engineered to comprise a number of functional combinations, as described herein, to produce a desired result. Using the particular CAR anti-CD19-4-1BB-CD3ζ as an example, the antibody (e.g., or antigen-binding fragment thereof such as an scFv) that binds a molecule can be substituted for an antibody that binds different molecule, as described herein (e.g., anti-CD20, anti-CD33, anti-CD123, etc., instead of anti-CD19). In other embodiments, the co-stimulatory molecule (4-1BB in this specific example) can also be varied with a different co-stimulatory molecule, e.g., CD28. In some embodiments, the stimulatory molecule (CD3ζ in this specific example), can be substituted with another known stimulatory molecule. In various embodiments, the transmembrane domain of the receptor can also be varied as desired. The design, production, and testing for functionality of such immune activating receptors can be readily determined by those of skill in the art. Similarly, the design, delivery into cells and expression of nucleic acids encoding such immune activating receptors are readily known and available in the art.
As used herein, the term “nucleic acid” refers to a polymer comprising multiple nucleotide monomers (e.g., ribonucleotide monomers or deoxyribonucleotide monomers). “Nucleic acid” includes, for example, genomic DNA, cDNA, RNA, and DNA-RNA hybrid molecules. Nucleic acid molecules can be naturally occurring, recombinant, or synthetic. In addition, nucleic acid molecules can be single-stranded, double-stranded or triple-stranded. In some embodiments, nucleic acid molecules can be modified. In the case of a double-stranded polymer, “nucleic acid” can refer to either or both strands of the molecule.
The term “nucleotide sequence,” in reference to a nucleic acid, refers to a contiguous series of nucleotides that are joined by covalent linkages, such as phosphorus linkages (e.g., phosphodiester, alkyl and aryl-phosphonate, phosphorothioate, phosphotriester bonds), and/or non-phosphorus linkages (e.g., peptide and/or sulfamate bonds). In certain embodiments, the nucleotide sequence encoding, e.g., a target-binding molecule linked to a localizing domain is a heterologous sequence (e.g., a gene that is of a different species or cell type origin).
The terms “nucleotide” and “nucleotide monomer” refer to naturally occurring ribonucleotide or deoxyribonucleotide monomers, as well as non-naturally occurring derivatives and analogs thereof. Accordingly, nucleotides can include, for example, nucleotides comprising naturally occurring bases (e.g., adenosine, thymidine, guanosine, cytidine, uridine, inosine, deoxyadenosine, deoxythymidine, deoxyguanosine, or deoxycytidine) and nucleotides comprising modified bases known in the art.
As will be appreciated by those of skill in the art, in some aspects, the nucleic acid further comprises a plasmid sequence. The plasmid sequence can include, for example, one or more sequences selected from the group consisting of a promoter sequence, a selection marker sequence, and a locus-targeting sequence.
As used herein, the gene encoding a target-binding molecule linked to a localizing domain is sometimes referred to as “LD-linked target-binding molecule.”
In certain embodiments, the target-binding molecule is an antibody or antigen-binding fragment thereof. As used herein, “antibody” means an intact antibody or antigen-binding fragment of an antibody, including an intact antibody or antigen-binding fragment that has been modified or engineered, or that is a human antibody. Examples of antibodies that have been modified or engineered are chimeric antibodies, humanized antibodies, multiparatopic antibodies (e.g., biparatopic antibodies), and multispecific antibodies (e.g., bispecific antibodies). Examples of antigen-binding fragments include Fab, Fab′, F(ab′)2, Fv, single chain antibodies (e.g., scFv), minibodies and diabodies.
A “Fab fragment” comprises one light chain and the CH1 and variable regions of one heavy chain. The heavy chain of a Fab molecule cannot form a disulfide bond with another heavy chain molecule.
An “Fc” region contains two heavy chain fragments comprising the CH2 and CH3 domains of an antibody. The two heavy chain fragments are held together by two or more disulfide bonds and by hydrophobic interactions of the CH3 domains.
A “Fab′ fragment” contains one light chain and a portion of one heavy chain that contains the VH domain and the CH1 domain and also the region between the CH1 and CH2 domains, such that an interchain disulfide bond can be formed between the two heavy chains of two Fab′ fragments to form a F(ab′)2 molecule.
A “F(ab′)2 fragment” contains two light chains and two heavy chains containing a portion of the constant region between the CH1 and CH′ domains, such that an interchain disulfide bond is formed between the two heavy chains. A F(ab′), fragment thus is composed of two Fab′ fragments that are held together by a disulfide bond between the two heavy chains.
The “Fv region” comprises the variable regions from both the heavy and light chains, but lacks the constant regions.
In a particular embodiment, the target-binding molecule is single-chain Fv antibody (“scFv antibody”). scFv refers to antibody fragments comprising the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. Generally, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the scFv to form the desired structure for antigen binding. For a review of scFv, see Pluckthun (1994) The Pharmacology Of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds. Springer-Verlag, New York, pp. 269-315. See also, PCT Publication No. WO 88/01649 and U.S. Pat. Nos. 4,946,778 and 5,260,203. By way of example, the linker between the VH and VL domains of the scFvs disclosed herein comprise, e.g., GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 41) or GGGGSGGGGSGGGGS (SEQ ID NO: 43). As would be appreciated by those of skill in the art, various suitable linkers can be designed and tested for optimal function, as provided in the art, and as disclosed herein.
The scFv that is part of the LD-linked target-binding molecule is not necessarily the same as the scFv that occurs in the context of, e.g., a chimeric antigen receptor (CAR) or a similar antibody-binding signaling receptor. In some embodiments, the scFv that is part of the LD-linked target-binding molecule is the same as the scFv that occurs in the context of, e.g., a chimeric antigen receptor (CAR) or a similar antibody-binding signaling receptor.
In some embodiments, the nucleic acid comprising a nucleotide sequence encoding a target-binding molecule (e.g., an scFv in the context of a LD-linked target-binding molecule) comprises one or more sequences that have at least 80%, at least 85%, at least 88%, at least 90%, at least 92%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to any one or more of SEQ ID NOs: 14, 15, 18, 19, 22, 23, 26, 27, 30, 31, 34, 35, 38, or 39.
The term “sequence identity” means that two nucleotide or amino acid sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least, e.g., 70% sequence identity, or at least 80% sequence identity, or at least 85% sequence identity, or at least 90% sequence identity, or at least 95% sequence identity or more. For sequence comparison, typically one sequence acts as a reference sequence (e.g., parent sequence), to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.
Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by visual inspection (see generally Ausubel et al., Current Protocols in Molecular Biology). One example of algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul et al., J. Mol. Biol. 215:403 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (publicly accessible through the National Institutes of Health NCBI internet server). Typically, default program parameters can be used to perform the sequence comparison, although customized parameters can also be used. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)).
In certain embodiments, the antibody (e.g., scFv) comprises VH and VL having amino acid sequences set forth in SEQ ID NO: 12 and 13, respectively; SEQ ID NO: 16 and 17, respectively; SEQ ID NO: 20 and 21, respectively; SEQ ID NO: 24 and 25, respectively; SEQ ID NO: 28 and 29, respectively; SEQ ID NO: 32 and 33, respectively; or SEQ ID NO: 36 and 37, respectively. In some embodiments, the antibody (e.g., scFv) comprises VH and VL having sequence that each have at least 90% sequence identity, at least 91% sequence identity, at least 92% sequence identity, at least 93% sequence identity, at least 94% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity, at least 99% sequence identity, or 100% sequence identity to the VH and VL sequences set forth in SEQ ID NO: 12 and 13, respectively; SEQ ID NO: 16 and 17, respectively; SEQ ID NO: 20 and 21, respectively; SEQ ID NO: 24 and 25, respectively; SEQ ID NO: 28 and 29, respectively; SEQ ID NO: 32 and 33, respectively; or SEQ ID NO: 36 and 37, respectively.
A “diabody” is a small antibody fragment with two antigen-binding sites. The fragments comprise a heavy chain variable region (VH) connected to a light chain variable region (VL) in the same polypeptide chain (VH-VL or VL-VH). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described in, e.g., patent documents EP 404,097; WO 93/11161; and Holliger et al., (1993) Proc. Natl. Acad. Sci. USA 90: 6444-6448.
In certain embodiments, the antibody is a triabody or a tetrabody. Methods of designing and producing triabodies and tetrabodies are known in the art. See, e.g., Todorovska et al., J. Immunol. Methods 248(1-2):47-66, 2001.
A “domain antibody fragment” is an immunologically functional immunoglobulin fragment containing only the variable region of a heavy chain or the variable region of a light chain. In some instances, two or more VH regions are covalently joined with a peptide linker to create a bivalent domain antibody fragment. The two VH regions of a bivalent domain antibody fragment may target the same or different antigens.
In some embodiments, the antibody is modified or engineered. Examples of modified or engineered antibodies include chimeric antibodies, multiparatopic antibodies (e.g., biparatopic antibodies), and multispecific antibodies (e.g., bispecific antibodies).
As used herein, “multiparatopic antibody” means an antibody that comprises at least two single domain antibodies, in which at least one single domain antibody is directed against a first antigenic determinant on an antigen and at least one other single domain antibody is directed against a second antigenic determinant on the same antigen. Thus, for example, a “biparatopic” antibody comprises at least one single domain antibody directed against a first antigenic determinant on an antigen and at least one further single domain antibody directed against a second antigenic determinant on the same antigen.
As used herein, “multispecific antibody” means an antibody that comprises at least two single domain antibodies, in which at least one single domain antibody is directed against a first antigen and at least one other single domain antibody is directed against a second antigen (different from the first antigen). Thus, for example, a “bispecific” antibody is one that comprises at least one single domain antibody directed against a first antigen and at least one further single domain antibody directed against a second antigen, e.g., different from the first antigen.
In some embodiments, the antibodies disclosed herein are monoclonal antibodies, e.g., murine monoclonal antibodies. Methods of producing monoclonal antibodies are known in the art. See, for example, Pluckthun (1994) The Pharmacology of Monoclonal Antibodies, Vol. 113, Rosenburg and Moore eds. Springer-Verlag, New York, pp. 269-315.
In various embodiments, the target-binding molecule in the context of a LD-linked target-binding molecule is a receptor or a ligand that binds to a target molecule. For example, that target-binding molecule can be a ligand that binds PD-1 (e.g., PD-L1 or PD-L2). Thus, as would be appreciated by those of skill in the art, the target-binding molecule can be an antibody, or a ligand/receptor that binds a target molecule.
As used herein, “linked” in the context of a LD-linked target-binding molecule refers to a gene encoding a target-binding molecule directly in frame (e.g., without a linker) adjacent to one or more genes encoding one or more localizing domains. Alternatively, the gene encoding a target-binding molecule may be connected to one or more gene encoding one or more localizing domains through a linker sequence, as described herein. Various suitable linkers known in the art can be used to tether the target-binding molecule to a localizing domain. For example, non-naturally occurring peptides, such as a polypeptide consisting of hydrophilic residues of varying length, or a (GGGGS)n (SEQ ID NO: 8) polypeptide, in which n is an integer of, e.g., 3-12, inclusive, can be used according to the present invention. In particular embodiments, the linker comprises, e.g., GGGGSGGGGS (SEQ ID NO: 62). In some embodiments, the linker comprises, e.g., GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 41). In various embodiments, peptide linkers having lengths of about 5 to about 100 amino acids, inclusive, can be used in the present invention. In certain embodiments, peptide linkers having lengths of about 20 to about 40 amino acids, inclusive, can be used in the present invention. In some embodiments, peptide linkers having lengths of at least 5 amino acids, at least 10 amino acids, at least 15 amino acids, at least 20 amino acids, at least 25 amino acids, at least 30 amino acids, at least 35 amino acids, or at least 40 amino acids can be used in the present invention. As would be appreciated by those of skill in the art, such linker sequences as well as variants of such linker sequences are known in the art. Methods of designing constructs that incorporate linker sequences as well as methods of assessing functionality are readily available to those of skill in the art.
In certain embodiments, the LD-linked target-binding molecule binds to a target expressed on the surface of an immune cell. In some embodiments, the LD-linked target-binding molecule inhibits the activity or function of the target molecule. By way of example, as disclosed herein, the LD-linked target-binding molecule can be designed to bind to, e.g., CD3, CD7, CD45, hB2MG, KIR2DL1, KIR2DL2/DL3, or NKG2A, thereby downregulating the cell surface expression of such molecules. Downregulation of such molecules can be achieved through, for example, localizing/targeting the molecules for degradation and/or internalization. In other embodiments, the LD-linked target-binding molecule renders the target inactive (e.g., the target can no longer interact and/or bind to its cognate ligand or receptor).
In some embodiments, the engineered immune cells of the present invention have enhanced therapeutic efficacy. As used herein, “enhanced therapeutic efficacy” refers to one or more of reduced graft-versus-host disease (GvHD) in a host, reduced or elimination of rejection by a host, extended survival in a host, reduced inhibition by the tumor in a host, reduced self-killing in a host, reduced inflammatory cascade in a host, or sustained CAR-mediated signal transduction in a host.
In certain embodiments of the present invention, the target-binding molecule in the context of a LD-linked target-binding molecule binds to a molecule in a CD3/T-cell receptor (TCR) complex, a cytokine, a human leukocyte antigen (HLA) Class I molecule, or a receptor that downregulates immune response.
In certain embodiments, a molecule in a CD3/TCR complex can be CD3ε, TCRα, TCRβ, TCRγ, TCRδ, CD3δ, CD3γ, or CD3ζ. In a particular embodiment, the molecule is CD3ε.
In another embodiment, the HLA Class I molecule is beta-2 microglobulin, α1-microglobulin, α2-microglobulin, or α3-microglobulin.
In other embodiments, a receptor that downregulates immune response is selected from, e.g., PD-1, CTLA-4, Tim3, killer immunoglobulin-like receptors (KIRs—e.g., KIR2DL1 (also known as CD158a), KIR2DL2/DL3 (also known as CD158b)), CD94 or NKG2A (also known as CD159a), protein tyrosine phosphatases such as Src homology region 2 domain-containing phosphatase (SHP)-1 and SHP-2. Thus, such receptors can be targeted by moiety LD-linked target-binding molecule, as described herein.
In various embodiments, examples of cytokines that can be targeted with moiety LD-linked target-binding molecule include, e.g., interleukin (IL)-6, IL-2, IL-4, IL-7, IL-10, IL-12, IL-15, IL-18, IL-21, IL-27, IL-35, interferon (IFN)-γ, IFN-β, IFN-α, tumor necrosis factor (TNF)-α, or transforming growth factor (TGF)-βα.
In a further aspect, the LD-linked target-binding molecule binds to a molecule selected from, e.g., CD2, CD4, CD5, CD7, CD8, CD30, CD38, CD45, CD52, or CD127.
Methods of producing antibodies and antibody fragments thereof against any target protein are well-known and routine in the art. Moreover, as exemplified herein, commercially available antibodies to various targets, e.g., CD3 and CD7 can be used to generate a LD-linked target-binding molecule, as exemplified herein. Antibodies known in the art, as well as fragments of antibodies (e.g., scFv) derived therefrom, can be used in the present invention, as exemplified herein.
In other aspects, the localizing domain of the LD-linked target-binding molecule comprises an endoplasmic reticulum (ER) retention sequence KDEL (SEQ ID NO: 4), or other ER or Golgi retention sequences such as KKXX (SEQ ID NO: 9), KXD/E (SEQ ID NO: 10) (where X can be any amino acid—see Gao C, et al., Trends in Plant Science 19: 508-515, 2014) and YQRL (SEQ ID NO: 11) (see Zhan J, et al., Cancer Immunol Immunother 46:55-60, 1998); a proteosome targeting sequence that comprises, e.g., “PEST” motif-SHGFPPEVEEQDDGTLPMSCAQESGMDRHPAACASARINV (SEQ ID NO: 7); and/or a sequence that targets the target-binding molecule to the cell membrane, such as the CD8a transmembrane domain, or the transmembrane of another single-pass membrane protein, as described herein (e.g., CD8α, CD8β, 4-1BB, CD28, CD34, CD4, FcεRIγ, CD16 (such as CD16A or CD16B), OX40, CD3λ, CD3ε, CD3γ, CD3δ, TCRα, CD32 (such as CD32A or CD32B), CD64 (such as CD64A, CD64B, or CD64C), VEGFR2, FAS, or FGFR2B). Examples of particular localizing domains (sequences) exemplified herein are shown in
As shown in
As would be appreciated by those of skill in the art, the immune activating receptor and/or the LD-linked target-binding molecule can be designed to bind to the targets disclosed herein, as well as variants of the targets disclosed herein. By way of example, an immune activating receptor and/or the LD-linked target-binding molecule can be designed to bind to a molecule in a CD3/TCR complex, or a naturally-occurring variant molecule thereof. Such naturally-occurring variants can have the same function as the wild-type form of the molecule. In other embodiments, the variant can have a function that is altered relative to the wild-type form of the molecule (e.g., confers a diseased state).
As would be appreciated by those of skill in the art, the various components of the LD-linked target-binding molecule constructs shown in
In further aspects, the present invention relates to the use of an engineered immune cell that comprises a nucleic acid comprising a nucleotide sequence encoding an immune activating receptor, and a nucleic acid comprising a nucleotide sequence encoding a target-binding molecule (e.g., scFv) linked to a localizing domain for treating cancer, comprising administering a therapeutic amount of the engineered immune cell to a subject in need thereof.
In another aspect, the present invention relates to the use of an engineered immune cell that comprises a nucleic acid comprising a nucleotide sequence encoding a chimeric antigen receptor (CAR) and a nucleic acid comprising a nucleotide sequence encoding a single-chain variable fragment (scFv) linked to a localizing domain for treating cancer, comprising administering a therapeutic amount of the engineered immune cell to a subject in need thereof.
In other aspects, the present invention relates to the use of an engineered immune cell that comprises a nucleic acid comprising a nucleotide sequence encoding an immune activating receptor, and a nucleic acid comprising a nucleotide sequence encoding a target-binding molecule (e.g., scFv) linked to a localizing domain for treating an autoimmune disorder, comprising administering a therapeutic amount of the engineered immune cell to a subject in need thereof.
In other aspects, the present invention also relates to the use of an engineered immune cell that comprises a nucleic acid comprising a nucleotide sequence encoding an immune activating receptor, and a nucleic acid comprising a nucleotide sequence encoding a target-binding molecule (e.g., scFv) linked to a localizing domain for treating an infectious disease, comprising administering a therapeutic amount of the engineered immune cell to a subject in need thereof.
In various embodiments, the immune activating receptor is a CAR (e.g., anti-CD19-4-1BB-CD3ζ CAR).
In other embodiments, the single-chain variable fragment (scFv) linked to a localizing domain is selected from any one or more constructs shown in
In some aspects, the engineered immune cell is administered by infusion into the subject. Methods of infusing immune cells (e.g., allogeneic or autologous immune cells) are known in the art. A sufficient number of cells are administered to the recipient in order to ameliorate the symptoms of the disease. Typically, dosages of 107 to 1010 cells are infused in a single setting, e.g., dosages of 109 cells. Infusions are administered either as a single 109 cell dose or divided into several 109 cell dosages. The frequency of infusions can be every 3 to 30 days or even longer intervals if desired or indicated. The quantity of infusions is generally at least 1 infusion per subject and preferably at least 3 infusions, as tolerated, or until the disease symptoms have been ameliorated. The cells can be infused intravenously at a rate of 50-250 ml/hr. Other suitable modes of administration include intra-arterial infusion, direct injection into tumor and/or perfusion of tumor bed after surgery, implantation at the tumor site in an artificial scaffold, intrathecal administration, and intraocular administration. Methods of adapting the present invention to such modes of delivery are readily available to one skilled in the art.
In certain aspects, the cancer to be treated is a solid tumor or a hematologic malignancy. Examples of hematologic malignancies include acute myeloid leukemia, chronic myelogenous leukemia, myelodysplasia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, multiple myeloma, Hodgkin and non-Hodgkin lymphoma. Examples of solid tumors include lung cancer, melanoma, breast cancer, prostate cancer, colon cancer, renal cell carcinoma, ovarian cancer, pancreatic cancer, hepatocellular carcinoma, neuroblastoma, rhabdomyosarcoma, brain tumor.
In another embodiment, the present invention relates to a method for producing an engineered immune cell of the present invention, comprising introducing into an immune cell a nucleic acid comprising a nucleotide sequence encoding an immune activating receptor, and a nucleic acid comprising a nucleotide sequence encoding a target-binding molecule linked to a localizing domain, thereby producing an engineered immune cell.
In certain embodiments, the nucleic acid comprising a nucleotide sequence is introduced into an immune cell ex vivo. In other embodiments, the nucleic acid comprising a nucleotide sequence is introduced into an immune cell in vivo.
In some embodiments, an “immune cell” includes, e.g., a T cell, a natural killer (NK) cell, an NK/T cell, a monocyte, a macrophage, or a dendritic cell.
The nucleic acid comprising a nucleotide sequence to be introduced can be a single bicistronic construct containing an immune activating receptor described herein and a target-binding molecule (e.g., scFv) linked to a localizing domain. As described herein, a single bicistronic construct can be prepared by inserting an internal ribosomal entry site (IRES) or a 2A peptide-coding region site between the 2 cDNAs encoding the immune activating receptor as described herein (e.g., CAR) and the target-binding molecule (e.g., scFv). The design of tricistronic delivery systems to delete more than one target should also be feasible. Alternatively, separate transductions (simultaneously or sequentially) of the individual constructs (e.g., CAR and LD-linked target-binding molecule) could be performed. Methods of introducing exogenous nucleic acids are exemplified herein, and are well-known in the art.
As used herein, the indefinite articles “a” and “an” should be understood to mean “at least one” unless clearly indicated to the contrary.
Methods
Cloning of scFv from Mouse Anti-Human CD3 Hybridoma
PLU4 hybridoma cells secreting an anti-human CD3 monoclonal antibody (IgG2a isotype; Creative Diagnostics, Shirley, N.Y.) were cultured in IMDM plus GlutaMAX medium (Life Technologies, Carlsbad, Calif.) with 20% fetal bovine serum (Thermo Fisher Scientific, Waltham, Mass.) and antibiotics. Total RNA was extracted using TRIzol reagent (Life Technologies), and cDNA was synthesized by M-MLV reverse transcriptase (Promega, Madison, Wis.) and Oligo(dT)15 primer (Promega). IgG Library Primer Set Mouse BioGenomics (US Biological, Salem, Mass.) was used to amplify the variable region of heavy chain (VH) and light chain (VL); PCR products were cloned into TOPO TA cloning kit for sequencing (Life Technologies). The VH and VL genes were assembled into scFv by a flexible linker sequence which encodes (Gly4Ser)4 using splicing by overlapping extension-PCR. Signal peptide domain of CD8α was subcloned by PCR using cDNA derived from human activated T cell from healthy donor, and connected to 5′ end of the VL fragment. The Myc tag (EQKLISEEDL; SEQ ID NO: 1) was added to C-terminus of VH by PCR using sense primer: 5′-ATATATGAATTCGGCTTCCACCATGGCCTTACCAGTGACC-3′ (SEQ ID NO: 2) and reverse primer: 5′-CAGATCTTCTTCAGAAATAAGTTTTTGTTCGGCTGAGGAGACTGTGAGAG-3′(SEQ ID NO: 3). Also the KDEL (SEQ ID NO: 4) coding sequence was generated after Myc tag by sense primer: 5′-ATATATGAATTCGGCTTCCACCATGGCCTTACCAGTGACC-3′ (SEQ ID NO: 5) and reverse primer: 5′-TATATACTCGAGTTACAACTCGTCCTTCAGATCTTCTTCAGAAATAAG-3′ (SEQ ID NO: 6). The synthesized gene consisting of CD8 signal peptide, scFv against human CD3, Myc tag and KDEL (SEQ ID NO: 4) sequence was subcloned into EcoRI and XhoI sites of the MSCV-IRES-GFP vector. Constructs in which myc-KDEL was replaced by other sequences were also made as listed in
The sequence of “PEST”-SHGFPPEVEEQDDGTLPMSCAQESGMDRHPAACASARINV (SEQ ID NO: 7) motif corresponding to amino acids 422-461 of mouse ornithine decarboxylase was obtained from GenBank (accession number NM_013614.2). Codon optimization and gene synthesis was done by GenScript (Piscataway, N.J.), and subcloned into the 3′ end of VH by PCR. The constructs were subcloned into EcoRI and XhoI sites of the MSCV-IRES-GFP vector.
Cloning of scFv Against Human CD7
The sequence scFv derived from murine TH69 (anti-CD7) antibody was obtained from literature (Peipp et al., Cancer Res 2002 (62): 2848-2855). After codon optimization, the synthesized gene consisting of CD8 signal peptide, scFv against human CD7, Myc tag and KDEL (SEQ ID NO: 4) sequence was subcloned into EcoRI and XhoI sites of the MSCV-IRES-GFP vector. Constructs in which myc-KDEL was replaced by other sequences were also made as listed in
Cloning of scFv Against Human Beta-2 Microglobulin (hB2MG)
The sequence scFv derived from murine BBM.1 (anti-hB2MG) IgG2b antibody was obtained from literature (Grovender, E. A. et al., Kidney Int. 2004; 65(1):310-322). After codon optimization, synthesized gene consists of CD8 signal peptide, scFv against human B2MG, Myc tag and KDEL (SEQ ID NO: 4) sequence was subcloned into EcoRI and XhoI sites of the MSCV-IRES-GFP vector.
Cloning of scFv Against Human KIR2DL1 and KIR2DL2/DL3
The amino acid sequence of human monoclonal antibody I-7F9 (anti-KIR2DL1, KIR2DL2, and KIR2DL3) was derived from published International Patent Application WO2006003179 A2 by Moretta et al. After codon optimization, the sequence of scFv was designed by connecting variable light (VL) region and variable heavy (VH) region with linker sequence. The synthesized gene consisting of CD8 signal peptide, scFv against human KIRs (KIR2DL1, KIR2DL2 and KIR2DL3), CD8 hinge and transmembrane domain, and KKMP sequence was subcloned into EcoRI and XhoI sites of the MSCV-IRES-GFP vector. Constructs in which KKMP was replaced by other sequences were also made as listed in
Cloning of scFv Against Human NKG2A
The sequence of murine antibody Z199 (anti-NKG2A) was derived from the published patent by Spee et al. (EP2247619 A1). After codon optimization, the sequence of scFv was designed by connecting variable light (VL) region and variable heavy (VH) region with linker sequence. The synthesized gene consisting of CD8 signal peptide, scFv against human NKG2A, CD8 hinge and transmembrane, and KKMP sequence was subcloned into EcoRI and XhoI sites of the MSCV-IRES-GFP vector. Constructs in which KKMP was replaced by other sequences were also made as listed in
Anti-CD19-4-1BB-CD3ζ CAR
This CAR was generated as previously described (Imai, C. et al., Leukemia. 2004; 18:676-684; Imai, C. et al., Blood. 2005; 106:376-383).
Gene Transduction, Cell Expansion, Flow Cytometric Analysis and Functional Studies
These were performed as previously described (Kudo, K et al., Cancer Res. 2014; 74(1):93-103).
Results
Generation of scFv Constructs
A schematic of the technology is outlined in
Downregulation of T-Cell Receptor in T Lymphocytes Expressing Anti-CD19-BB-ζ CAR
To determine whether the proposed strategy could be applied to generate immune cells expressing CAR and lacking one or more markers, T-cell receptor (TCR) expression was downregulated in anti-CD19 CAR T-cells.
To be expressed on the cell membrane, the CD3/TCR complex requires assembly of all its components (TCRα, TCRβ, CD3δ, CD3ζ, CD3γ, CD3ζ). Lack of one component prevents CD3/TCR expression and, therefore, antigen recognition. In preliminary studies, the scFv from an anti-CD3ε hybridoma (purchased from Creative Diagnostics, Shirley, N.Y.) was cloned and generated the constructs containing KDEL (SEQ ID NO: 4), PEST, CD8a transmembrane domain or others as shown in
The constructs disclosed herein were transduced in the CD3/TCR+ Jurkat cell line using a murine stem cell virus (MSCV) retroviral vector containing green fluorescent protein (GFP). Percentage of GFP+ cells after transduction was >90% in all experiments.
Staining with anti-TCRαβ antibody of Jurkat cells or human peripheral blood T lymphocytes showed that down regulation of CD3ε expression was associated with dowregulation of TCRαβ expression (
Next, it was determined whether the anti-CD3 scFv-myc KDEL could be expressed simultaneously with an anti-CD19-4-1BB-CD3ζ CAR. As shown in
To assess whether CAR could signal in Jurkat cells with downregulated CD3/TCR, the expression of the activation markers CD69 and CD25 was tested, and exocytosis of lytic granules was measured by CD107a expression in Jurkat cells co-cultured with the CD19+ leukemia cell line OP-1. As shown in
Accordingly, CD3/TCR can be effectively downregulated in CAR-T cells using the anti-CD3 scFv-myc KDEL construct without affecting T cell activation, degranulation and proliferation driven by the CAR.
Downregulation of CD7
It was determined whether the strategy that successfully modulated CD3/TCR expression could be applied to other surface molecules. For this purpose, CD7 expression was modulated. The scFv sequence was derived from that published by Peipp et al. (Cancer Res 2002 (62): 2848-2855), which was linked to the CD8 signal peptide and the myc-KDEL sequence as illustrated in
Downregulation of HLA-Class I
The strategy was then applied to downregulate another surface molecule, HLA class I.
HLA class I consists of polymorphic a chains and a non-polymorphic chain termed β2-microglobulin. Knock-down of the latter subunit results in abrogation of HLA (MHC in the mouse) Class I expression (Koller, B H et al., Science. 1990; 248(4960):1227-1230). An scFv reacting with β2-microglobulin was used to suppress expression of HLA Class I in immune cells.
The scFv sequence was derived from that published by Grovender et al. (Kidney Int. 2004; 65(1):310-322), which was linked to the CD8 signal peptide and the myc KDEL sequence as illustrated in
Dowregulation of Inhibitory Receptors in NK Cells
To determine if the strategy outlined above would also apply to surface molecules expressed in other immune cells, downregulation of function of the inhibitory receptor KIR2DL1, KIR2DL2/DL3 and NKG2A was tested in NK cells.
To downregulate MR receptors, an scFv reacting with KIR2DL1 and KIR2DL2/DL3 was used to suppress their expression in NK cells. The scFv sequence was derived from that published by Moretta et al. (patent WO2006003179 A2), which was linked to the CD8 signal peptide and the ER retention sequences as illustrated in
To downregulate NKG2A, an scFv reacting with NKG2A was used to suppress its expression in NK cells. The scFv sequence, which was derived from published European Patent Application No. EP2247619 A1 by Spee et al. was linked to the CD8 signal peptide and the ER retention sequences as illustrated in
The teachings of all patents, published applications and references cited herein are incorporated by reference in their entirety.
While this invention has been particularly shown and described with references to example embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
This application is a continuation of U.S. patent application Ser. No. 16/943,400, filed Jul. 30, 2020, which is a continuation of U.S. patent application Ser. No. 15/548,577, filed Aug. 3, 2017, now U.S. Pat. No. 10,765,699, which is a 371 U.S. National Phase Application of International Patent Cooperation Treaty Application PCT/SG2016/050063, filed Feb. 5, 2016, which claims benefit to U.S. Provisional Application No. 62/112,765, filed Feb. 6, 2015, and U.S. Provisional Application No. 62/130,970, filed Mar. 10, 2015, the disclosures of which are incorporated herein by reference in their entirety for all purposes.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4946778 | Ladner et al. | Aug 1990 | A |
| 5260203 | Ladner et al. | Nov 1993 | A |
| 6326193 | Liu et al. | Dec 2001 | B1 |
| 7887805 | Pedersen | Feb 2011 | B2 |
| 8119775 | Moretta et al. | Feb 2012 | B2 |
| 8399645 | Campana et al. | Mar 2013 | B2 |
| 8580714 | Almagro | Nov 2013 | B2 |
| 8637258 | Padkjaer et al. | Jan 2014 | B2 |
| 8697359 | Zhang | Apr 2014 | B1 |
| 8796427 | Spee et al. | Aug 2014 | B2 |
| 8981065 | Moretta et al. | Mar 2015 | B2 |
| 9181527 | Sentman | Nov 2015 | B2 |
| 9273283 | Sentman | Mar 2016 | B2 |
| 9422368 | Spee et al. | Aug 2016 | B2 |
| 9683042 | Lee | Jun 2017 | B2 |
| 9902936 | Moretta et al. | Feb 2018 | B2 |
| 10273280 | Ma et al. | Apr 2019 | B2 |
| 10550183 | Png et al. | Feb 2020 | B2 |
| 10730942 | Pule et al. | Aug 2020 | B2 |
| 10765699 | Campana et al. | Sep 2020 | B2 |
| 11440958 | Png et al. | Sep 2022 | B2 |
| 20030105000 | Pero | Jun 2003 | A1 |
| 20060034834 | Marasco et al. | Feb 2006 | A1 |
| 20070036773 | Cooper et al. | Feb 2007 | A1 |
| 20090196850 | Romagne et al. | Aug 2009 | A1 |
| 20120282256 | Campana et al. | Nov 2012 | A1 |
| 20130287748 | June et al. | Oct 2013 | A1 |
| 20140068797 | Doudna et al. | Mar 2014 | A1 |
| 20140120622 | Gregory et al. | May 2014 | A1 |
| 20140186387 | Lauer et al. | Jul 2014 | A1 |
| 20160060341 | Lee et al. | Mar 2016 | A1 |
| 20160256488 | Wu | Sep 2016 | A1 |
| 20160272999 | Duchateau et al. | Sep 2016 | A1 |
| 20160312182 | Sentman | Oct 2016 | A1 |
| 20170119820 | Moriarity et al. | May 2017 | A1 |
| 20170204372 | Mohler et al. | Jul 2017 | A1 |
| 20170335331 | Zhao et al. | Nov 2017 | A1 |
| 20180066034 | Ma et al. | Mar 2018 | A1 |
| 20180086831 | Pule et al. | Mar 2018 | A1 |
| 20180179280 | Png et al. | Jun 2018 | A1 |
| 20180371052 | Ma et al. | Dec 2018 | A1 |
| 20190002912 | Lu et al. | Jan 2019 | A1 |
| 20190038733 | Campana et al. | Feb 2019 | A1 |
| 20190046571 | Campana et al. | Feb 2019 | A1 |
| 20190345217 | Ma et al. | Nov 2019 | A1 |
| 20200087398 | Qasim et al. | Mar 2020 | A1 |
| 20210046112 | Campana et al. | Feb 2021 | A1 |
| 20210395779 | Ismail et al. | Dec 2021 | A1 |
| Number | Date | Country |
|---|---|---|
| 103492406 | Jan 2014 | CN |
| 0404097 | Dec 1990 | EP |
| 2247619 | Nov 2010 | EP |
| 3169773 | May 2017 | EP |
| 3322801 | May 2018 | EP |
| 3359168 | Aug 2018 | EP |
| 3474867 | May 2019 | EP |
| 3568467 | Nov 2019 | EP |
| H03219896 | Sep 1991 | JP |
| H09501824 | Feb 1997 | JP |
| 2001516766 | Oct 2001 | JP |
| 2008506368 | Mar 2008 | JP |
| 2008518021 | May 2008 | JP |
| 2009511495 | Mar 2009 | JP |
| 2010537671 | Dec 2010 | JP |
| 2011510047 | Mar 2011 | JP |
| 2014507118 | Mar 2014 | JP |
| 6895380 | Jun 2021 | JP |
| WO-8801649 | Mar 1988 | WO |
| WO-9311161 | Jun 1993 | WO |
| WO-9914353 | Mar 1999 | WO |
| WO-0129058 | Apr 2001 | WO |
| WO-0196584 | Dec 2001 | WO |
| WO-03051926 | Jun 2003 | WO |
| WO-2005017163 | Feb 2005 | WO |
| WO-2006003179 | Jan 2006 | WO |
| WO-2009092805 | Jul 2009 | WO |
| WO-2012079000 | Jun 2012 | WO |
| WO-2014011984 | Jan 2014 | WO |
| WO 2014098319 | Jun 2014 | WO |
| WO-2014098319 | Jun 2014 | WO |
| WO-2014124143 | Aug 2014 | WO |
| WO-2015075468 | May 2015 | WO |
| WO-2015150771 | Oct 2015 | WO |
| WO-2016055551 | Apr 2016 | WO |
| WO-2016102965 | Jun 2016 | WO |
| WO-2016126213 | Aug 2016 | WO |
| WO-2016138491 | Sep 2016 | WO |
| WO-2018098306 | May 2018 | WO |
| WO-2019032916 | Feb 2019 | WO |
| WO-2020102589 | May 2020 | WO |
| Entry |
|---|
| Coleman et al. Effects of amino acid sequence changes on antibody-antigen interactions; Research in Immunology, 1994; 145(1): 33-36. |
| Rudikoff et al., Single amino acid substitution altering antigen-binding specificity; Proc. Natl Acad. Sci. USA 1982; pp. 1979-1983. |
| Burgess et al ., Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue; The Journal of Cell Biology, 1990 ; pp. 2129-2138. |
| Almagro & Frans son, Frontiers in Bioscience 2008; 13: 1619-33. |
| Böldicke et al., Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the ER, J. Cell. Mol. Med., 11(1):54-70 (2007). |
| Dotti et al. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunological Reviews, vol. 257, Issue 1, pp. 107-126 (2014). |
| Grimshaw, B.D. et al., BGST Abstract Mar. 9, 2012, abstract P023, “Creating a ‘null’ T cell for use in adoptive immunotherapy”, British Society for Gene and Cell Therapy 2012, hltp://www.bsqct.orq, Human Gene Therapy, 22 pages. |
| Hegde, M. et al., “Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma”, Molecular Therapy, 2013, vol. 21, pp. 2087-2101. |
| Imamura. M. et al., “Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15”, Blood, 2014, vol. 124, pp. 1081-1088. |
| Kloss, C.C. et al., “Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells”, Nature Biotechnology, 2013, vol. 31, pp. 71-75. |
| Lanitis et al. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused anti-tumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res 1(1):43-53(2013). |
| Lo, A.S.Y et al., “Harnessing the tumour-derived cytokine, CSF-1, to co-stimulate Tcell growth and activation”, Molecular Immunology, 2008, vol. 45, pp. 1276-1287. |
| Marschall, Andrea LJ, et al. “Specific in vivo knockdown of protein function by intrabodies”, Taylor & Francis Group, LLC, Nov./Dec. 2015, vol. 7, Issue 6, pp. 1010-1035. |
| Milone et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17:1453-1464 (2009). |
| Rossig, C. et al., “Genetic modification of T lymphocytes for adoptive immunotherapy”, Molecular Therapy, 2004, vol. 10, pp. 5-18. |
| Rowley, J. et al., “Expression of IL-15RA or an IL-15/1L-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis”, European Journal of Immunology, 2009, vol. 39, pp. 491-506. |
| Sanz, L. et al., “Antibodies and gene therapy: teaching old ‘magic bullets’ new tricks”, Trends in Immunology, 2004, vol. 25, pp. 85-91. |
| Zhou, P. et al., “Cells transfected with a non-neutralizing antibody gene are resistant to HIV infection: targeting the endoplasmic reticulum and trans-Golgi network”, The Journal of Immunology, 1998, vol. 160, pp. 1489-1496. |
| Aandahl et al., CD7 is a differentiation marker that identifies multiple CD8 T cell effector subsets, J Immunol 2003; 170:2349-2355. |
| Alanen et al., Beyond KDEL: the role of positions 5 and 6 in determining ER localization. J. Mol. Biol. (2011) 409, 291-297. Available online Apr. 6, 2011. |
| Alarcon et al., Assembly of the human T cell receptor-CD3 complex takes place in the endoplasmic reticulum and involves intermediary complexes between the CD3-gamma.delta.epsilon core and single T cell receptor alpha or beta chains, Journal of Biological Chemistry, Feb. 25, 1988;263(6):2953-61. |
| Altschul et al. Basic local alignment search tool. J Mol Biol 215(3):403-410 (1990). |
| Anti-CD3 epsilon [OKT-3 (muromonab)]. Absolute Antibody. Website. Copyright 2021. Retrieved Dec. 26, 2021 at URL: https://absoluteantibody.com/product/anti-cd3-epsilon-okt-3- . . . 4 pages. |
| Anti-CD3D monoclonal antibody, clone PLU4 (DCABH-10124). Product Information. CD Creative Diagnostics. Publication date unknown. 2 pages. |
| Anti-TCR [BMA031]. Absolute Antibody. Website. Copyright 2021. Retrieved Dec. 26, 2021 at URL: https://absoluteantibody.com/product/anti-tcr-bma031/4 pages. |
| Appelbaum. Haematopoietic cell transplantation as immunotherapy. Nature, vol. 411, pp. 385-389 (2001). |
| Applicants' arguments for U.S. Appl. No. 15/821,170, pp. 6-10; filed on Jun. 27, 2019. |
| Arafat et al. Antineoplastic effect of anti-erbB-2 intrabody is not correlated with scFv affinity for its target. Cancer Gene Therapy, vol. 7, No. 9, 2000: pp. 1250-1256. |
| Austyn et al. T cell activation by anti-CD3 antibodies: function of Fc receptors on B cell blasts, but not resting B cells, and CD18 on the responding T cells. Eur J Immunol 17:1329-1335 (1987). |
| Böldicke et al. Functional inhibition of transitory proteins by intrabody-mediated retention in the endoplasmatic reticulum. Methods 56 (2012) 338-350. Available online Oct. 20, 2011. |
| Bleakley et al., Molecules and mechanisms of the graft-versus-leukaemia effect, Nature Reviews, Cancer, May 2004;4(5):371-80. |
| Boettcher et al, Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR, Mol Cell. May 21, 2015;58:575-85. |
| Bonilla et al., Targeted gene disruption of murine CD7, Int Immunol. Dec. 1997;9(12):1875-83. |
| Brentjens et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. Mar. 20, 2013;5(177):177ra38. 9 pages. |
| Brentjens et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. Mar. 2003;9(3):279-86. |
| Brentjens et al., “Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts,” Clin Cancer Res I 3(18):5426-5435, Sep. 15, 2007. |
| Brentjens et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. Nov. 3, 2011;118(18):4817-28. Prepublished online Aug. 17, 2011. |
| Brudno et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol 34(10):1112-1121 (2016). |
| Burgess et al. Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue. J Cell Biol. 111:2129-2138 (1990). |
| Burns et al. Two monoclonal anti-human T lymphocyte antibodies have similar biologic effects and recognize the same cell surface antigen. J Immunol 1982; 129:1451-1457. |
| Campana et al. 4-1BB chimeric antigen receptors. Cancer J. Mar.-Apr. 2014;20(2):134-40. |
| Campana et al., Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia. Blood. Apr. 6, 2017;129(14):1913-1918, Epub Feb. 6, 2017. |
| Ceuppens et al. Failure of OKT3 monoclonal antibody to induce lymphocyte mitogenesis: a familial defect in monocyte helper function. J Immunol, vol. 134, No. 3, pp. 1498-1502 (Mar. 1985). |
| Chang et al. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res 73(6):1777-86 (Mar. 15, 2013). Published online Jan. 9, 2013. |
| Clevers et al., The T cell receptor/CD3 complex: a dynamic protein ensemble, Annual Review of Immunology, 1988;6:629-62. |
| Colman, P.M., “Effects of amino acid sequence changes on antibody-antigen interactions”, Res. Immunology, Jan. 1994, vol. 145, pp. 33-36. |
| Cooley et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood (2010) 116 (14): 2411-2419. |
| Cooper, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood. Feb. 15, 2003;101(4):1637-44. Epub Oct. 10, 2002. |
| Co-pending U.S. Appl. No. 17/862,797, inventors Campana; Dario et al., filed on Jul. 12, 2022. |
| Co-pending U.S. Appl. No. 17/865,292, inventors Png; Yi Tian et al., filed on Jul. 14, 2022. |
| Coustan-Smith et al., Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia, Blood. Oct. 1, 2002;100(7):2399-402. Prepublished online May 31, 2002. |
| Coustan-Smith et al., Early T-cell precursor leukemia: a subtype of very high-risk acute lymphoblastic leukemia, Lancet Oncol. Feb. 2009 ; 10(2): 147-156. |
| Dai et al., Tolerance and efficacy of autologous or donor-derived T cells expression CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncolmmunology, 4:11, e1027469 (2015). 12 pages. |
| Davila. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6(224):224ra25 (2014). |
| EP16746922.0 Extended European Search Report dated Sep. 21, 2018. |
| EP17874643.4 Extended European Search Report dated Jun. 3, 2020. |
| EP18844536.5 Extended European Search Report dated Mar. 18, 2021. |
| EP19883740.3 Extended European Search Report dated Jun. 28, 2022. |
| Eshhar et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA, vol. 90, pp. 720-724 (Jan. 1993). |
| Eyquem et al., Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection, Nature. Mar. 2, 2017; 543(7643): 113-117. |
| Fedorov et al. Novel Approaches to Enhance the Specificity and Safety of Engineered T Cells. Cancer J. 2014 ; 20(2): 160-165. |
| Final office action for U.S. Appl. No. 15/821,170, pp. 1-11, filed on Sep. 27, 2018. |
| Frankel et al., Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin, Leukemia & Lymphoma, vol. 26, pp. 287-298 (1997). |
| Gale. Cellular and Molecular Basis of Cancer. Merck Manual Professional Version. Last full review/revision Nov. 2020. Content last modified Nov. 2020. Retrieved Jan. 8, 2021 at URL: https://www.merckmanuals.com/professional/hematology-and-oncology/overview-of-cancer/cellular-and-molecular-basis-of-cancer# 8 pages. |
| Gan et al. Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion. Cancers 2020, 12, 1872. Published Jul. 11, 2020. 22 pages. |
| Gao et al. Retention mechanisms for ER and Golgi membrane proteins. Trends in Plant Science, vol. 19, Issue 8, pp. 508-515 (Aug. 2014). |
| Geiger et al. Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. Blood 98(8):2364-2371 (2001). |
| Geiger et al. The TCR zeta-chain immunoreceptor tyrosine-based activation motifs are sufficient for the activation and differentiation of primary T lymphocytes. The Journal of Immunology, 1999, 162: 5931-5939. |
| Ghosh et al., Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity, Nat Med. Feb. 2017 ; 23(2): 242-249. |
| Giebel et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood (2003) 102 (3): 814-819. |
| Gomes-Silva et al., CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies, Blood. 2017;130(3):285-296. Prepublished online May 24, 2017. |
| Grimshaw. Developing a universal T cell for use in adoptive immunotherapy (thesis), University College London (2015). Retrieved Aug. 22, 2022 at URL: http://discovery.ucl.ac.uk/1470207/1/Grimshaw%20Ben%20Thesis.pdf. 267 pages. |
| Grimshaw et al. Creating a Null T Cell for Adoptive Immunotherapy. Poster. Mar. 9, 2012. One page. |
| Grovender et al. Single-chain antibody fragment-based adsorbent for the extracorporeal removal β2-microglobulin. Kidney International, vol. 65 (2004), pp. 310-322. |
| Grupp et al. Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia. N Engl J Med 368;16, pp. 1509-1508 (Apr. 18, 2013). With correction published N. Engl J. Med (2016) 374(10) 998. |
| Haegert et al. Co-expression of surface immunoglobulin and T3 on hairy cells. Scand J Haematol 1986;37:196-202. |
| Haso et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013;121(7):1165-1174. Prepublished online Dec. 14, 2012. |
| Haynes et al., Human lymphocyte antigens: production of a monoclonal antibody that defines functional thymus-derived lymphocyte subsets. Proc Natl Acad Sci USA Nov. 1979; 76(11):5829-5833. |
| Haynes et al. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. J Immunol 2002; 169:5780-5786. |
| Haynes et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood. Nov. 1, 2002;100(9):3155-63. Published online Jul. 5, 2002. |
| Hegde, M. et al., Supplementary Material for “Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma”, Molecular Therapy, 2013, vol. 21, pp. 2087-2101. Retrieved Jan. 6, 2022 from URL: https://ars.els-cdn.com/content/image/1-s2.0-S1525001616309315-mmc1.pdf. 9 pages. |
| Henikoff, et al. Amino acid substitution matrices from protein blocks. Proc Natl Acad Sci U S A. Nov. 15, 1992;89(22):10915-9. |
| Hexham et al. Influence of relative binding affinity on efficacy in a panel of anti-CD3 scFv immunotoxins. Molecular Immunology 38 (2001) 397-408. |
| Holliger et al. “Diabodies”: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA, vol. 90, pp. 6444-6448 (Jul. 1993). |
| Hombach et al. Tumor-Specific T Cell Activation by Recombinant Immunoreceptors: CD3ζ Signaling and CD28 Costimulation are Simultaneously Required for Efficient IL-2 Secretion and Can be Integrated Into One Combined CD28/CD3ζ Signaling Receptor Molecule. J Immunol 2001; 167:6123-6131. |
| Ibragimova. Stability of the β-Sheet of the WW Domain: A Molecular Dynamics Simulation Study. Biophysical Journal, vol. 77, pp. 2191-2198 (Oct. 1999). |
| Imai et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia (2004) 18, 676-684. |
| Imai et al. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood (2005) 106 (1): 376-383. |
| Imamura. M. et al., Supplementary Material for “Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15”, Blood, 2014, vol. 124, pp. 1081-1088. Retrieved Jan. 6, 2021 at URL: https://ash.silverchair-cdn.com/ash/content_public/journal/blood/124/7/10.1182_blood-2014-02-556837/4/blood-2014-02-556837-1.pdf?Expires=1644340511&Signature=uyyKt0KS8WtXpVUILTgok2RyynmzBJgE2vCNIDD4xdwCv13vsg0goCLOpQLU˜KVPtlTvlHtmCLeX2MhA7mcxzXy˜ydDqrj6rHeZEBNohY4NOkmjpH9529c9SCChMFB1n80TH-cM-MgQfrETegs4oK6vjiveJODaZP6TfW1gGK˜5JUAn5LesZfPv9W28NmBfMoAOMVeX4Pz54V˜9dWaBcCfXCR7vOrx1N8cpbxmlAumSziwKqxNCy79dwOL6ddz3joiyKtMiGNuY1c6l1f6b˜MwbLxZ3jKI6EE-giQZhSxfLm2ctwuCbOMj8RIHCM4cO5a2zlKMAM6dut-dafGbQaRQ_&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA. 11 pages. |
| Inukai et al., Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15, British Journal of Haematology, 156, 358-365 (2011). First published online Nov. 30, 2011. |
| Jabbour et al., New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia, Cancer 2015;121:2517-28. Published online Apr. 17, 2015. |
| Jackson et al., Identification of a consensus motif for retention of transmembrane proteins in the endoplasmic reticulum, EMBO J. Oct. 1990; 9(10): 3153-3162. |
| Jain et al., Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype, Blood. 2016;127(15):1863-1869. Prepublished online Jan. 18, 2016. |
| Joshi et al. Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies. mAbs, vol. 4, Issue 6, pp. 686-693 (2012). Published online: Aug. 28, 2012. |
| Kalos, et al., “T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia”, Science Translation Medicine 3.95 (2011):95ra73-95ra73. |
| Kamiya et al. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. J Clin Invest. 2019;129(5):2094-2106. |
| Kim et al. High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS One 6:e18556 (2011). |
| Kita et al., Clinical importance of CD7 expression in acute myelocytic leukemia. The Japan Cooperative Group of Leukemia/Lymphoma, Blood, May 1, 1993;81(9):2399-405. |
| Kloss, C.C. et al., Supplementary Text and Figures for “Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells”, Nature Biotechnology, 2013, vol. 31, pp. 71-75. Retrieved Jan. 6, 2021 at URL: https://static-content.springer.com/esm/art%3A10.1038%2Fnbt.2459/MediaObjects/41587_2013_BFnbt2459_MOESM2_ESM.pdf. 5 pages. |
| Kloss. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nature Technology, vol. 31, No. 1, pp. 71-75 (Jan. 2013). Published online Dec. 16, 2012. |
| Kochenderfer et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709-2720. Published online Dec. 8, 2011. |
| Kochenderfer et al., Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor, Journal of Clinical Oncology, Feb. 20, 2015; 33(6); pp. 540-549. Published online Aug. 25, 2014. |
| Kochenderfer et al., Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation, Blood. 2013;122(25):4129-4139. |
| Kolb et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood, vol. 86. No. 5 Sep. 1, 1995: pp. 2041-2050. |
| Kotteas et al. Immunotherapy for pancreatic cancer. J Cancer Res Clin Oncol (2016) 142:1795-1805. Published online Feb. 3, 2016. |
| Kudo et al. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res 74(1):93-103 (2013). |
| Lee, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. Jul. 10, 2014;124(2):188-95. doi: 10.1182/blood-2014-05-552729. Epub May 29, 2014. |
| Lee et al., Immunologic Characterization of CD7-Deficient Mice, J Immunol 1998; 160:5749-5756. |
| Lee et al., T cells expressing CD 19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet, Feb. 7, 2015; 385 (9967); pp. 517-528. Epub Oct. 13, 2014. |
| Leung et al., Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia, Blood. 2012;120(2):468-472. Prepublished online Apr. 19, 2012. |
| Lo et al. Harnessing the tumour-derived cytokine, CSF-1, to co-stimulate T-cell growth and activation. Molecular Immunology 45 (2008) 1276-1287. Available online Oct. 24, 2007. |
| Long et al., 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors, Nature Medicine, Jun. 2015; 21(6):581-90. Epub May 4, 2015. |
| Lorentzen et al. CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia. Scandinavian Journal of Immunology, 2015, 82, 307-319. |
| Maetzig et al.: Gammaretroviral vectors: biology, technology and application. Viruses 3(6):677-713 doi:10.3390/v3060677 (2011). |
| Maher et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotech 20(1):70-75 (2002). |
| Mamonkin et al., A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies, Blood. 2015;126(8):983-992. Prepublished online Jun. 8, 2015. |
| Manabe et al., Interleukin-4 induces programmed cell death (apoptosis) in cases of high-risk acute lymphoblastic leukemia. Blood. Apr. 1, 1994; 83(7):1731-7. |
| Marasco et al. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. PNAS USA 90:7889-7893 (1993). |
| Marks et al., Management of adults with T-cell lymphoblastic leukemia, Blood. Mar. 2, 2017;129(9):1134-1142, Epub Jan. 23, 2017. |
| Maude, et al., Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N. Engl J. Med (2014) 371(16) 1507-1517. With correction published N. Engl J. Med 374(10):998 (2016). |
| Mihara et al., Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma, J Immunother. Sep. 2009; 32(7):737-43. |
| Miller et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051-3057 (2005). |
| Miller. Therapeutic applications: natural killer cells in the clinic. Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 247-253. |
| Munro et al., A C-terminal signal prevents secretion of luminal ER proteins, Cell. Mar. 13, 1987;48:899-907. Retrieved Apr. 7, 2022 at URL: https://bio.davidson.edu/molecular/MunPelham/mufixed.html. |
| Kochenderfer et al., Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 (Blood, 2010, 116:4099-4102) (Year: 2010). |
| Needleman et al. A general method applicable to the search for similarities in the amino acid sequence of two proteins. Journal of molecular biology 48(3):443-453 (1970). |
| Neumann et al., Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations, Blood Cancer Journal 2, e55, Jan. 27, 2012. 7 pages. |
| Non final office action for U.S. Appl. No. 15/821,170, pp. 1-10, filed on Mar. 27, 2019. |
| Non final office action for U.S. Appl. No. 15/821,170, pp. 1-12, filed on Apr. 5, 2018. |
| Office Action Summary for Non-final office action of U.S. Appl. No. 15/821,170, filed Apr. 5, 2018. |
| Pardoll. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12(4):252-264(2012). |
| Park et al. Are all chimeric antigen receptors created equal? J Clin Oncol. Feb. 20, 2015;33(6):651-3. Epub Jan. 20, 2015. |
| Park et al., CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date, Blood. 2016;127(26):3312-3320. |
| PCT/SG2016/050063 International Search Report and Written Opinion dated May 9, 2016. |
| PCT/US2017/063048 International Search Report and Written Opinion dated Mar. 5, 2018. |
| PCT/US2018/046137 International Search Report and Written Opinion dated Oct. 29, 2018. |
| PCT/US2019/061549 International Search Report and Written Opinion dated Jan. 30, 2020. |
| Pearson and Lipman, Improved tools for biological sequence comparison, Proc. Nat. Acad Sci USA., 85:2444-2448, (1988). |
| Peipp et al. A Recombinant CD7-specific Single-Chain Immunotoxin Is a Potent Inducer of Apoptosis in Acute Leukemic T Cells. Cancer Research 62, pp. 2848-2855 (May 15, 2002). |
| Pluckthun, “Antibodies from Escherichia coli,” in Handbook of Experimental Pharmacology; The Pharmacology of Monoclonal Antibodies; vol. 113, Chapter 11, pp. 269-315 (1994), Rosenburg and Moore eds., Springer-Verlag, New York. |
| Poirot et al. Multiplex Genome-Edited T-cell Manufacturing Platform for Off-the-Shelf Adoptive T-cell Immunotherapies. Cancer Research 75(18):3853-3864 (2015). |
| Porter et al., Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725-733 (2011). With correction published N. Engl J. Med (2016) 374(10) 998. |
| Porter et al. Induction of Graft-versus-Host Disease as Immunotherapy for Relapsed Chronic Myeloid Leukemia. N Engl J Med 1994; 330:100-106. |
| Raetz et al., T-cell acute lymphoblastic leukemia. American Society of Hematology, pp. 580-588 (2016). Retrieved Apr. 14, 2022 at URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142501/pdf/bloodbook-2016-580.pdf. |
| Reshef et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med 367;3 pp. 135-145 (Jul. 12, 2012). |
| Rosenberg et al. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348(6230):62-68 (2015). |
| Rowley, J. et al., Supplementary Information for “Expression of IL-15RA or an IL-15/1L-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis”, European Journal of Immunology, 2009, vol. 39, pp. 491-506. Retrieved Jan. 6, 2022 at URL: https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Feji.200838594&file=eji_200838594_sm_SupplInfoFig.pdf. 6 pages. |
| Rubnitz et al. NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia. J Clin Oncol. Feb. 20, 2010; 28(6): 955-959. |
| Ruggeri et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295(5562):2097-2100 (2002). |
| Sadelain et al. The Basic Principles of Chimeric Antigen Receptor Design. Cancer Discov. Apr. 2013; 3(4): 388-398. |
| Sato et al. Single domain intrabodies against WASP inhibit TCR-induced immune responses in transgenic mice T cells. Sci Rep. Oct. 21, 2013;3:3003. 10 pages. |
| Schumann, et al. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci U S A. Aug. 18, 2015;112(33):10437-42. doi: 10.1073/pnas.1512503112. Epub Jul. 27, 2015. |
| Schwartz. T cell anergy. Annu Rev Immunol. 2003;21:305-34. First published online as a Review in Advance on Dec. 5, 2002. |
| Sharma et al., “Novel cancer immunotherapy agents with survival benefit: recent successes and next steps,” Nat Rev Cancer, 11(11):805-812 (2011). |
| Shikano et al., Membrane receptor trafficking: Evidence of proximal and distal zones conferred by two independent endoplasmic reticulum localization signals, PNAS May 13, 2003 100 (10) 5783-5788. |
| Shimasaki et al. A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy, 2012; 14: 830-840. |
| Shimasaki et al., Natural killer cell reprogramming with chimeric immune receptors, Methods Mol Biol. 2013;969:203-20. |
| Slavin et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood (1996) 87 (6): 2195-2204. |
| Smith et al. Comparison of Biosequences. Advances in Applied Mathematics. 2:482-489 (1981). |
| Smith et al. T cell activation by anti-T3 antibodies: Comparison of IgG1 and IgG2b switch variants and direct evidence for accessory function of macrophage Fc receptors. Eur J Immunol 16:478-486 (1986). |
| Strebe et al. Functional knockdown of VCAM-1 at the posttranslational level with ER retained antibodies. Journal of Immunological Methods 341 (2009) 30-40. Available online Nov. 25, 2008. |
| Su et al., CRISPR-Cas9 mediated efficient PD-I disruption on human primary T cells from cancer patients, Sci Rep 6, 20070, Published: Jan. 28, 2016. 14 pages. |
| Till et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119(17):3940-3950 (2012). |
| Topp et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. Jun. 20, 2011;29(18):2493-8. |
| Torikai et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 119(24):5697-5705 (2012). |
| Tsai et al., Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases, Nature Reviews Genetics, vol. 17, pp. 300-312 (May 2016). Published online Apr. 18, 2016. |
| Turtle et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell All patients. J Clin Invest 126(6):2123-2138 (2016). |
| U.S. Appl. No. 15/548,577 Notice of Allowance dated May 4, 2020. |
| U.S. Appl. No. 15/548,577 Office Action dated Jan. 14, 2019. |
| U.S. Appl. No. 15/548,577 Office Action dated Jul. 20, 2018. |
| U.S. Appl. No. 15/548,577 Office Action dated Sep. 17, 2019. |
| U.S. Appl. No. 15/821,153 First Action Interview—Office Action dated Dec. 2, 2020. |
| U.S. Appl. No. 15/821,153 First Action Interview Pilot Program Pre-Interview Communication dated Aug. 24, 2020. |
| U.S. Appl. No. 15/821,153 Notice of Allowance dated Jun. 23, 2022. |
| U.S. Appl. No. 15/821,153 Office Action dated Apr. 19, 2021. |
| U.S. Appl. No. 15/821,153 Office Action dated Jan. 13, 2022. |
| U.S. Appl. No. 15/821,153 Score search results SEQ ID Nos. 1 and 2. Searches run on Jan. 21, 2020. Retrieved Nov. 28, 2020 at URL: http://score.uspto.gov/ScoreAccessWeb/getItem.htm?AppID=15821153&seID=09323b6 . . . . |
| U.S. Appl. No. 15/821,170 Notice of Allowance dated Sep. 18, 2019. |
| U.S. Appl. No. 16/100,117 Office Action dated Aug. 12, 2022. |
| U.S. Appl. No. 16/100,117 Office Action dated Dec. 9, 2021. |
| U.S. Appl. No. 16/100,117 Office Action dated May 3, 2021. |
| U.S. Appl. No. 16/100,120 Office Action dated Aug. 2, 2019. |
| U.S. Appl. No. 16/100,120 Office Action dated Feb. 24, 2020. |
| U.S. Appl. No. 16/100,120 Office Action dated Jan. 28, 2019. |
| U.S. Appl. No. 16/100,120 Office Action dated Oct. 6, 2020. |
| Van Wauwe et al. Human T lymphocyte activation by monoclonal antibodies; OKT3, but not UCHT1, triggers mitogenesis via an interleukin 2-dependent mechanism. J Immunol, vol. 133, No. 1, pp. 129-132 (Jul. 1984). |
| Verneris et al. Natural Killer Cell Consolidation for Acute Myelogenous Leukemia: A Cell Therapy Ready for Prime Time? J Clin Oncol. Feb. 20, 2010; 28(6): 909-910. |
| Verwilghen et al. Differences in the stimulating capacity of immobilized anti-CD3 monoclonal antibodies: variable dependence on interleukin-1 as a helper signal for T-cell activation. Immunology 72:269-276 (1991). |
| Vivier, Eric et al., Innate or adaptive immunity? The example of natural killer cells, Science (New York,N.Y.) vol. 331,6013 (2011): 44-9. doi:10.1126/science.1198687. |
| Vodinelich et al., A monoclonal antibody (WT1) for detecting leukemias of T-cell precursors (T-ALL), Blood, vol. 62, No. 5; pp. 1108-1113 (Nov. 1983). |
| Wang et al. Expression and characterization of recombinant soluble monkey CD3 molecules: mapping the FN18 polymorphic epitope. Molecular Immunology 40:1179-1188 (2004). |
| Weetall et al. T-cell depletion and graft survival induced by anti-human CD3 immunotoxins in human CD3ε transgenic mice. Transplantation, vol. 73, 1658-1666, No. 10 (May 27, 2002). |
| Wheeler et al. Intrabody and intrakine strategies for molecular therapy. Molecular Therapy, vol. 8, No. 3, pp. 355-366, Sep. 2003. |
| Wunderlich et al. OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues. Blood. 2014;123(24):e134-e144. |
| Yang et al., Challenges and opportunities of allogeneic donor-derived CAR T cells, Current Opinion in Hematology, Nov. 2015; 22 (6); pp. 509-515. |
| Yeoh et al., Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell, vol. 1, pp. 133-143 (Mar. 2022). |
| Zang et al. The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res 13(18) pp. 5271-5279 (Sep. 15, 2007). |
| Zhan et al. Modification of ricin A chain, by addition of endoplasmic reticulum (KDEL) or Golgi (YQRL) retention sequences, enhances its cytotoxicity and translocation. Cancer Immunology, Immunotherapy. vol. 46, pp. 55-60 (1998). |
| Zhang et al., The genetic basis of early T-cell precursor acute lymphoblastic leukaemia, Nature, vol. 481, pp. 157-163, Jan. 12, 2012. |
| Zhao et al. Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T cells. Cancer Cell 28(4):415-428 (2015). |
| Applicant's Remarks for U.S. Appl. No. 15/548,577, pp. 5-14; filed on Oct. 22, 2018. |
| Applicant's Remarks for U.S. Appl. No. 15/548,577, pp. 5-15; filed on Mar. 14, 2019. |
| Score Search Results Details for U.S. Appl. No. 15/548,577 and Search Result 20190107_143513_us-15-548-577-37.rag. Search run on Jan. 7, 2019. Copy retrieved Sep. 11, 2019 at http://score.uspto.gov/ScoreAccessWeb/getItem.htm?AppId=15548577&seqId=09323b67 . . . 4 pages. |
| Score Search Results Details for U.S. Appl. No. 15/548,577 and Search Result 20190107_143514_us-15-548-577-36.rapbm. Search run on Jan. 7, 2019. Copy retrieved Sep. 11, 2019 at http://score.uspto.gov/ScoreAccessWeb/getItem.htm?AppId=15548577&seqId=09323b67 . . . 4 pages. |
| Score Search Results Detail for U.S. Appl. No. 17/862,721 and Search Results 20220829_091720_us-17-862-721-16.rag. Search run on Aug. 29, 2022. Copy retrieved Aug. 30, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17862721&docId=bc544287-1664-44c7-9aff-7ec7ba8cb7ea&itemName=20220829_091720 . . . 14 pages. |
| Score Search Results Detail for U.S. Appl. No. 17/862,721 and Search Results 20220829_091720_us-17-862-721-16.rai. Search run on Aug. 29, 2022. Copy retrieved Aug. 30, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17862721&docId=131a34de-dcc5-448f-b75f-7ea24f699275&itemName=20220829_091720_ . . . 8 pages. |
| Score Search Results Detail for U.S. Appl. No. 17/862,721 and Search Results 20220829_091720_us-17-862-721-16.rapm. Search run on Aug. 29, 2022. Copy retrieved Aug. 30, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17862721&docId=e6f49583-c02c-4eee-a87c-e0ece396955c&itemName=20220829_091720 . . . 10 pages. |
| Score Search Results Detail for U.S. Appl. No. 17/862,721 and Search Results 20220829_091720_us-17-862-721-17.rag. Search run on Aug. 29, 2022. Copy retrieved Aug. 30, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17862721&docId=cbb41ae5-1511-498f-ac7c-0b33abd2492f&itemName=20220829_091720 . . . 15 pages. |
| Score Search Results Detail for U.S. Appl. No. 17/862,721 and Search Results 20220829_091720_us-17-862-721-17.rai. Search run on Aug. 29, 2022. Copy retrieved Aug. 31, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17862721&docId=73e892a9-d59f-4aff-8df1-883c983c2966&itemName=20220829_091720_u . . . 8 pages. |
| Score Search Results Detail for U.S. Appl. No. 17/862,721 and Search Results 20220829_091720_us-17-862-721-17.rapm. Search run on Aug. 29, 2022. Copy retrieved Aug. 31, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17862721&docId=9851a8bc-7a77-4e69-985e-903a1f2622ae&itemName=20220829_09172 . . . 10 pages. |
| Score Search Results Detail for U.S. Appl. No. 17/862,721 and Search Results 20220829_091720_us-17-862-721-17.rpr. Search run on Aug. 29, 2022. Copy retrieved Aug. 31, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17862721&docId=e04b2be2-c5c8-4cba-b806-cd02a1efe868&itemName=20220829_091720_ . . . 7 pages. |
| Score Search Results Detail for U.S. Appl. No. 17/862,721 and Search Results 20220829_091720_us-17-862-721-20.rai. Search run on Aug. 29, 2022. Copy retrieved Aug. 31, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17862721&docId=d17ad86f-3b93-47e9-a94e-a9258afaa3e3&itemName=20220829_091720_ . . . 9 pages. |
| Score Search Results Detail for U.S. Appl. No. 17/862,721 and Search Results 20220829_091720_us-17-862-721-20.rapm. Search run on Aug. 29, 2022. Copy retrieved Aug. 31, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17862721&docId=5747899e-d2f6-4407-8197-6ae6e43ac551&itemName=20220829_09172 . . . 11 pages. |
| Score Search Results Detail for U.S. Appl. No. 17/862,721 and Search Results 20220829_091720_us-17-862-721-20.rpr. Search run on Aug. 29, 2022. Copy retrieved Aug. 31, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17862721&docId=8db4eb9f-566a-448b-8a1b-9244e2b8fOee&itemName=20220829_091720_ . . . 7 pages. |
| Score Search Results Detail for U.S. Appl. No. 17/862,721 and Search Results 20220829_091720_us-17-862-721-21.rag. Search run on Aug. 29, 2022. Copy retrieved Aug. 31, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17862721&docId=69e4190a-317d-4f26-9846-c30ab0601669&itemName=20220829_09172 . . . 14 pages. |
| Score Search Results Detail for U.S. Appl. No. 17/862,721 and Search Results 20220829_091720_us-17-862-721-21.rai. Search run on Aug. 29, 2022. Copy retrieved Aug. 31, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17862721&docId=a9c72e86-3699-4e4c-8110-8367d0fe6cf4&itemName=20220829_091720_ . . . 8 pages. |
| Score Search Results Details for U.S. Appl. No. 15/548,577 and Search Result 20190107_143513_us-15-548-577-37.rag. Search run on Jan. 7, 2019. Copy retrieved Jan. 8, 2019 at http://score.uspto.gov/ScoreAccessWeb/getItem.htm?AppId=15548577&seqId=09323b678 . . . 21 pages. |
| Score Search Results Details for U.S. Appl. No. 15/548,577 and Search Result 20190107_143514_us-15-548-577-36.rapbm. Search run on Jan. 7, 2019. Copy retrieved Jan. 8, 2019 at http://score.uspto.gov/ScoreAccessWeb/getItem.htm?AppId=15548577&seqId=09323b678 . . . 13 pages. |
| Score Search Results Details for U.S. Appl. No. 15/548,577 and Search Result 20190107_143514_us-15-548-577-37.rai. Search run on Jan. 7, 2019. Copy retrieved Jan. 8, 2019 at http://score.uspto.gov/ScoreAccessWeb/getItem.htm?AppId=15548577&seqId=09323b678 . . . 11 pages. |
| Score Search Results Details for U.S. Appl. No. 15/548,577 and Search Result 20190107_145543_us-15-548-577-32.rag. Search run on Jan. 7, 2019. Copy retrieved Jan. 8, 2019 at http://score.uspto.gov/ScoreAccessWeb/getItem.htm?AppId=15548577&seqId=09323b678 . . . 23 pages. |
| Score Search Results Details for U.S. Appl. No. 15/548,577 and Search Result 20190107_145544_us-15-548-577-32.rai. Search run on Jan. 7, 2019. Copy retrieved Jan. 8, 2019 at http://score.uspto.gov/ScoreAccessWeb/getItem.htm?AppId=15548577&seqId=09323b678 . . . 4 pages. |
| Score Search Results Details for U.S. Appl. No. 15/548,577 and Search Result 20190107_145544_us-15-548-577-32.rapbm. Search run on Jan. 7, 2019. Copy retrieved Jan. 8, 2019 at http://score.uspto.gov/ScoreAccessWeb/getItem.htm?AppId=15548577&seqId=09323b678 . . . 6 pages. |
| Score Search Results Details for U.S. Appl. No. 15/548,577 and Search Result 20190107_145544_us-15-548-577-33.rai. Search run on Jan. 7, 2019. Copy retrieved Jan. 8, 2019 at http://score.uspto.gov/ScoreAccessWeb/getItem.htm?AppId=15548577&seqId=09323b678 . . . 4 pages. |
| Score Search Results Details for U.S. Appl. No. 15/548,577 and Search Result 20190107_145544_us-15-548-577-33.rapbm. Search run on Jan. 7, 2019. Copy retrieved Jan. 8, 2019 at http://score.uspto.gov/ScoreAccessWeb/getItem.htm?AppId=15548577&seqId=09323b678 . . . 12 pages. |
| Score Search Results Details for U.S. Appl. No. 15/821,153 and Search Result 20200121_090346_us-15-821-153-1.rag. Search run on Jan. 21, 2020. Copy retrieved Aug. 18, 2020 at http://score.uspto.gov/ScoreAccessWeb/getItem.htm?AppId=15821153&seqId=09323b67 . . . 23 pages. |
| Score Search Results Details for U.S. Appl. No. 15/821,153 and Search Result 20200121_090346_us-15-821-153-2.rag. Search run on Jan. 21, 2020. Copy retrieved Aug. 18, 2020 at http://score.uspto.gov/ScoreAccessWeb/getItem.htm?AppId=15821153&seqId=09323b67 . . . 23 pages. |
| Score Search Results Details for U.S. Appl. No. 15/821,153 and Search Result 20200121_090346_us-15-821-153-2.rup. Search run on Jan. 21, 2020. Copy retrieved Aug. 18, 2020 at http://score.uspto.gov/ScoreAccessWeb/getItem.htm?AppId=15821153&seqId=09323b67 . . . 20 pages. |
| Score Search Results Details for U.S. Appl. No. 15/821,153 and Search Result 20200121_090347_us-15-821-153-1.rai. Search run on Jan. 21, 2020. Copy retrieved Aug. 18, 2020 at http://score.uspto.gov/ScoreAccessWeb/getItem.htm?AppId=15821153&seqId=09323b67 . . . 13 pages. |
| Score Search Results Details for U.S. Appl. No. 15/821,153 and Search Result 20200121_090347_us-15-821-153-1.rapbm. Search run on Jan. 21, 2020. Copy retrieved Aug. 18, 2020 at http://score.uspto.gov/ScoreAccessWeb/getItem.htm?AppId=15821153&seqId=09323b67 . . . 12 pages. |
| Score Search Results Details for U.S. Appl. No. 15/821,153 and Search Result 20200121_090347_us-15-821-153-2.rai. Search run on Jan. 21, 2020. Copy retrieved Aug. 18, 2020 at http://score.uspto.gov/ScoreAccessWeb/getItem.htm?AppId=15821153&seqId=09323b67 . . . 10 pages. |
| Score Search Results Details for U.S. Appl. No. 17/865,292 and Search Result 20220830_095119_us-17-865-292-23.rng. Search run on Aug. 30, 2022. Copy retrieved Nov. 29, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17865292&docId=2706fc1d-bbe9-44aa-9e87-af53511fa556&itemName=20220830_095119_ . . . 30 pages. |
| Score Search Results Details for U.S. Appl. No. 17/865,292 and Search Result 20220830_095119_us-17-865-292-24.rge. Search run on Aug. 30, 2022. Copy retrieved Nov. 29, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17865292&docId=937d1952-762a-4e3c-8c32-88e2288b7c98&itemName=20220830_09511 . . . 38 pages. |
| Score Search Results Details for U.S. Appl. No. 17/865,292 and Search Result 20220830_095119_us-17-865-292-24.rng. Search run on Aug. 30, 2022. Copy retrieved Nov. 29, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17865292&docId=5d 142fad-7410-4f70-a9be-89ec64a56333&itemName=20220830_095119 . . . 30 pages. |
| Score Search Results Details for U.S. Appl. No. 17/865,292 and Search Result 20220830_095120_us-17-865-292-23.rni. Search run on Aug. 30, 2022. Copy retrieved Nov. 29, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17865292&docId=f186dad7-ae7f-43af-8b02-3a44197ca02a&itemName=20220830_095120 . . . 14 pages. |
| Score Search Results Details for U.S. Appl. No. 17/865,292 and Search Result 20220830_095120_us-17-865-292-23.rnpbm. Search run on Aug. 30, 2022. Copy retrieved Nov. 29, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17865292&docId=900cc5f4-4ac6-4475-8128-b78583119326&itemName=20220830_095120 . . . 15 pages. |
| Score Search Results Details for U.S. Appl. No. 17/865,292 and Search Result 20220830_095120_us-17-865-292-23.rnpm. Search run on Aug. 30, 2022. Copy retrieved Nov. 29, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17865292&docId=83e35439-1 c58-4872-9143-2ca07009e445&itemName=20220830_09512 . . . 14 pages. |
| Score Search Results Details for U.S. Appl. No. 17/865,292 and Search Result 20220830_095120_us-17-865-292-24.rni. Search run on Aug. 30, 2022. Copy retrieved Nov. 29, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17865292&docId=17851e24-e7ef-41ff-a8b5-aa4f6678e368&itemName=20220830_095120_ . . . 14 pages. |
| Score Search Results Details for U.S. Appl. No. 17/865,292 and Search Result 20220830_095120_us-17-865-292-24.rnpbm. Search run on Aug. 30, 2022. Copy retrieved Nov. 29, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17865292&docId=e4980578-9557-44cc-bef2-957c3463b150&itemName=20220830_09512 . . . 15 pages. |
| Score Search Results Details for U.S. Appl. No. 17/865,292 and Search Result 20220830_095120_us-17-865-292-24.rnpm. Search run on Aug. 30, 2022. Copy retrieved Nov. 29, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17865292&docId=6ff15723-3306-45a1-9b09-bf77ca07f66f&itemName=20220830_095120_ . . . 14 pages. |
| Score Search Results Details for U.S. Appl. No. 17/865,292 and Search Result 20220830_095126_us-17-865-292-1.rag. Search run on Aug. 30, 2022. Copy retrieved Nov. 29, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17865292&docId=50a35438-b529-44da-9ce4-08ae532d9cbb&itemName=20220830_09512 . . . 14 pages. |
| Score Search Results Details for U.S. Appl. No. 17/865,292 and Search Result 20220830_095126_us-17-865-292-1.rup. Search run on Aug. 30, 2022. Copy retrieved Nov. 29, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId =17865292&docId=3479308a-3992-4b0e-aafc-63fe41 5f5435&itemName=20220830_095126 . . . 24 pages. |
| Score Search Results Details for U.S. Appl. No. 17/865,292 and Search Result 20220830_095126_us-17-865-292-2.rag. Search run on Aug. 30, 2022. Copy retrieved Nov. 29, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17865292&docId=0abe17f7-a1be-47ae-8ac9-1ed2ce4b6fff&itemName=20220830_095126_ . . . 15 pages. |
| Score Search Results Details for U.S. Appl. No. 17/865,292 and Search Result 20220830_095126_us-17-865-292-2.rup. Search run on Aug. 30, 2022. Copy retrieved Nov. 29, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17865292&docId=52fe6611-57d2-47cf-8720-b5b8014489d7&itemName=20220830_095126 . . . 26 pages. |
| Score Search Results Details for U.S. Appl. No. 17/865,292 and Search Result 20220830_095127_us-17-865-292-1.rapm. Search run on Aug. 30, 2022. Copy retrieved Nov. 29, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17865292&docId=8dd0ad77-f537-4b76-acd7-7af59c64da7c&itemName=20220830_095127 . . . 10 pages. |
| Score Search Results Details for U.S. Appl. No. 17/865,292 and Search Result 20220830_095127_us-17-865-292-1.rapn. Search run on Aug. 30, 2022. Copy retrieved Nov. 29, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17865292&docId=6364333c-58f2-4a2c-9307-bebec296487b&itemName=20220830_095127 . . . 8 pages. |
| Score Search Results Details for U.S. Appl. No. 17/865,292 and Search Result 20220830_095127_us-17-865-292-23.rge. Search run on Aug. 30, 2022. Copy retrieved Nov. 29, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17865292&docId=4c3d2764-7905-458d-80d9-b4fdab416ce6&itemName=20220830_095119 . . . 38 pages. |
| Score Search Results Details for U.S. Appl. No. 17/865,292 and Search Result 20220830_095127_us-17-865-292-2.rai. Search run on Aug. 30, 2022. Copy retrieved Nov. 29, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17865292&docId=e59c8342-56e0-4eed-90bd-fdf88ef33e70&itemName=20220830_095127_ . . . 8 pages. |
| Score Search Results Details for U.S. Appl. No. 17/865,292 and Search Result 20220830_095127_us-17-865-292-2.rapm. Search run on Aug. 30, 2022. Copy retrieved Nov. 29, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17865292&docId=76f2dfb7-3a6a-4cd5-83ac-f19f906ea899&itemName=20220830_095127_ . . . 10 pages. |
| Score Search Results Details for U.S. Appl. No. 17/865,292 and Search Result 20220830_095127_us-17-865-292-2.rapn. Search run on Aug. 30, 2022. Copy retrieved Nov. 29, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17865292&docId=abf74f2f-2ed9-499f-8be2-a36d94faf3c1&itemName=20220830_095127_u . . . 10 pages. |
| Score Search Results Details for U.S. Appl. No. 17/865,292 and Search Result 20220830_095127_us-17-865-292-2.rpr. Search run on Aug. 30, 2022. Copy retrieved Nov. 29, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17865292&docId=5f37e4aa-e455-4865-b025-b5f96a8af474&itemName=20220830_095127_ . . . 7 pages. |
| Score Search Results Details for U.S. Appl. No. 17/865,292 and Search Result 20220830_095127_us-17-865-292-1.rai. Search run on Aug. 30, 2022. Copy retrieved Dec. 6, 2022 at score.uspto.gov/ScoreAccessWeb/getItemDetail?appId=17865292&docId=ba251fa1-cde9-4fe8-91f1-9e547d9afc25&itemName=20220830_095127_u . . . 8 pages. |
| U.S. Appl. No. 17/865,292 Office Action dated Dec. 2, 2022. |
| EP22180254.9 Extended European Search Report dated Jan. 16, 2023. |
| Number | Date | Country | |
|---|---|---|---|
| 20220347219 A1 | Nov 2022 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62130970 | Mar 2015 | US | |
| 62112765 | Feb 2015 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16943400 | Jul 2020 | US |
| Child | 17862721 | US | |
| Parent | 15548577 | US | |
| Child | 16943400 | US |
